Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IDEV 6.42 Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious Puberty
Revolutionary Treatment for Children Now Available
Jun 25, 2007 8:45:00 AM
LEXINGTON, Mass., June 25 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the launch and availability of SUPPRELIN(R) LA (histrelin acetate) subcutaneous implant, 50mg, for the treatment of children with Central Precocious Puberty (CPP). The Company has completed all pre-launch activities and has shipped initial launch quantities to specialty pharmacies. The Indevus sales force has completed their training activities and has begun detailing and marketing SUPPRELIN LA.
"I am extremely pleased to announce the introduction of SUPPRELIN LA. We believe the unique attributes of SUPPRELIN LA establish a new standard of convenience for patients, families and physicians," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "SUPPRELIN LA offers a rapid suppression of hormones and sustained efficacy for a full year while other therapies require injections every three to four weeks. I am also very pleased that as a result of an extensive pre-launch planning effort, we have been able to bring this much needed treatment to patients and physicians in less than two months following FDA approval."
Paul Saenger, M.D., Professor of Pediatrics, Albert Einstein College of Medicine stated, "SUPPRELIN LA provides patients and their families a rapid and sustained treatment option that significantly reduces the inconvenience of frequent dosing and may improve long-term compliance. SUPPRELIN LA achieves and maintains excellent suppression of peak LH and sex steroid levels for one year in children with CPP and is well tolerated. Importantly, feedback from parents and patients indicate nearly uniform enthusiasm about this form of treatment as compared to traditional injections."
Indevus will be hosting a virtual press briefing with leading experts on Central Precocious Puberty and new treatment options at the MAGIC Foundation Annual Educational Conference on Growth Disorders July 19-22 in Chicago, IL. The MAGIC Foundation is the leading patient support organization on growth disorders in children. For more information on the press briefing, contact Emily Butler at 202-955-6222.
About SUPPRELIN LA
SUPPRELIN LA was approved by the U.S. Food and Drug Administration (FDA) on May 3, 2007 and is a once-yearly implant which utilizes the Company's patented Hydron implant technology. The implant is inserted subcutaneously in the inner aspect of the upper arm and is specifically designed to provide a continuous release over 12 months of approximately 65mcg/day of the gonadotropin releasing hormone (GnRH) analog histrelin.
FDA approval was based on the review of data from clinical studies conducted in children 4-11 years of age. A total of 47 children, 44 female and 3 male, were studied in two trials over 9 to 18 months of treatment. The most commonly reported adverse reaction was implant site reaction. A long- term follow-up study is on-going.
Prescribing Information
Complete prescribing information for SUPPRELIN LA is available from the Company upon request.
About Central Precocious Puberty
Central Precocious Puberty is the premature development of secondary sex characteristics that normally occur during puberty. In females, premature development is usually defined as earlier than 8 years of age, and in males, as earlier than 9 years of age. Children with CPP have an increased likelihood of psycho-social problems and also show significantly advanced bone age that can lessen their ability to attain full adult height.
About Indevus
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, DELATESTRYL(R) to treat male hypogonadism, and SUPPRELIN(R) LA, for central precocious puberty. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.
Forward Looking Statements
Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, VANTAS(R), SUPPRELIN(R) LA and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Indevus
Michael W. Rogers
Executive Vice President and CFO
(781)861-8444
Brooke D. Wagner
Vice President, Corporate Communications
(781)402-3410
SOURCE Indevus Pharmaceuticals, Inc.
----------------------------------------------
Michael W. Rogers
Executive Vice President and CFO
+1-781-861-8444
Brooke D. Wagner
Vice President
Corporate Communications
+1-781-402-3410
both for Indevus
ADF 7.88 ACM Managed Dollar Income Fund, Inc. Announces Expiration of Tender Offer and Preliminary Results
Jun 25, 2007 8:44:00 AM
NEW YORK, June 25 /PRNewswire-FirstCall/ -- ACM Managed Dollar Income Fund, Inc. (NYSE: ADF) (the "Fund") announced today its tender offer for 1,024,685 of its issued and outstanding shares of common stock representing approximately 5% of the Fund's outstanding shares expired Friday, June 22, 2007 at 12:00 Midnight Eastern Time. Shares tendered may be withdrawn at any time prior to 5:00 p.m. Eastern Time on June 26, 2007.
Based upon current information, approximately 2,139,456 shares were tendered, of which approximately 64,591 shares were tendered pursuant to notices of guaranteed delivery. Because the number of shares tendered exceeds 1,024,685 shares, the tender offer has been oversubscribed. Therefore, in accordance with the terms of the tender offer, the Fund will purchase shares on a pro rata basis (disregarding fractions) from all tendering stockholders, in accordance with the number of shares tendered by or on behalf of each stockholder. Based on preliminary information, the proration for each stockholder is estimated to be 46.5% of the shares properly tendered. These numbers are subject to adjustment and should not be regarded as final. The actual number of shares to be purchased will be announced at a later date. Management of the Fund anticipates acceptance on June 28, 2007 of 1,024,685 shares properly tendered and not withdrawn and that payment for such shares will be made on or about July 2, 2007. The purchase price of properly tendered shares is the net asset value per share determined as of the close of regular trading session of the New York Stock Exchange today.
The Fund is a non-diversified, closed-end U.S. registered management investment company whose investment adviser is AllianceBernstein L.P. As of June 22, 2007 the Fund's total net assets were approximately $170 million.
SOURCE ACM Managed Dollar Income Fund, Inc.
----------------------------------------------
Shareholder Contact
+1-800-219-4218
PTN 1.99 King Pharmaceuticals and Palatin Technologies Announce End-of-Phase 2 Meeting With FDA for Bremelanotide
Jun 25, 2007 8:44:00 AM
CRANBURY, N.J., and BRISTOL, Tenn., June 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has scheduled an End-of-Phase 2 meeting to discuss clinical study results with bremelanotide for the treatment of erectile dysfunction (ED). Palatin Technologies submitted a meeting request to FDA in May 2007; FDA has scheduled the meeting for August 2007.
"We look forward to discussing our Phase 2 results and plans for Phase 3 at the upcoming meeting with FDA and moving to Phase 3 trials as soon as possible," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. The purpose of the End-of-Phase 2 meeting is to determine the safety of proceeding to Phase 3, to evaluate the Phase 3 plan and protocols and the adequacy of current studies, and to identify any additional information necessary to support a marketing application.
Palatin previously announced positive results of the Phase 2b clinical trials evaluating ED in 726 non-diabetic and 294 diabetic patients at the American Urological Association Annual Meeting and at the 9th European Society for Sexual Medicine Congress. The Phase 2b clinical trials were double blind, placebo-controlled, parallel doses trials that included a 1 month run-in period and a 3 month treatment period. The results showed that up to 50% of ED patients were restored to a normal level of function.
About ED
ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's lead product candidate, bremelanotide, is currently in Phase 2 clinical trials for both male and female sexual dysfunction. Palatin's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, Palatin has entered into collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.
About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect managements' current views of future events and operations, including, but not limited to, statements pertaining to the proposed indications for bremelanotide; the significance of the results from the clinical trials of bremelanotide; and the conduct of future clinical trials. Some important factors which may cause results to differ materially from such forward-looking statements include dependence on the actual results of the companies' bremelanotide development activities; dependence on the companies' abilities to fund development of bremelanotide; dependence on the companies' abilities to complete clinical trials as anticipated; dependence on the availability and cost of raw materials; dependence on the unpredictability of the duration and results of the U.S Food and Drug Administration's ("FDA") review of Investigational New Drug Applications ("IND"), New Drug Applications ("NDA"), and supplemental New Drug Applications, ("sNDAs") and/or the review of other regulatory agencies worldwide; dependence on compliance with FDA and other government regulations that relate to King's and Palatin's respective businesses; dependence on King's and Palatin's abilities to successfully manufacture bremelanotide; and dependence on changes in general economic and business conditions; changes in current pricing levels; changes in federal and state laws and regulations; changes in competition; unexpected changes in technologies and technological advances; and manufacturing capacity constraints. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2006 and Form 10-Q for the quarter ended March 31, 2007 and Palatin's Form 10-K for the year ended June 30, 2006 and Form 10-Q for the quarters ended September 30, 2006, December 31, 2006 and March 31, 2007, which are on file with the U.S. Securities and Exchange Commission. The companies do not undertake to publicly update or revise any of their forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
EXECUTIVE OFFICES
PALATIN TECHNOLOGIES, INC.
4C CEDAR BROOK DRIVE, CRANBURY, NEW JERSEY 08512
KING PHARMACEUTICALS, INC.
501 FIFTH STREET, BRISTOL, TENNESSEE 37620
SOURCE Palatin Technologies, Inc.
----------------------------------------------
For Palatin Technologies: Stephen T. Wills
CPA
MST
EVP- Operations - Chief Financial Officer of Palatin Technologies
Inc.
+1-609-495-2200
info@palatin.com; For Palatin Institutional Investors and Media: Carney Noensie of Burns McClellan
+1-212-213-0006
cnoensie@burnsmc.com
for Palatin Technologies
Inc.; or For King Pharmaceuticals: James E. Green (for all King inquiries)
Executive Vice President
Corporate Affairs of King Pharmaceuticals
Inc.
+1-423-989-8125
TLCV 5.10 TLCVision Announces Two New TLC Laser Eye Centers(R)
Jun 25, 2007 8:41:00 AM
ST. LOUIS, MISSOURI -- (MARKETWIRE) -- 06/25/07 -- TLC Vision Corporation (TSX: TLC)(NASDAQ: TLCV), North America's premier eye care services company, announced today the opening of two new TLC Laser Eye Centers® (TLC). The Company has opened a center located in Portland, Oregon, which is the first TLC center in that state. In addition, the Company has opened a second location in Chicago, Illinois, which will leverage marketing activities currently underway and expand its presence in that already successful market.
Both of these centers will operate under the new TLC model, which combines the strength of the Company's optometric co-management and health plan relationships with aggressive pricing and direct to consumer advertising. This strategy leverages the strong TLC brand that has performed more procedures than any other company in the world. These two new centers brings the total number of TLC centers to 80.
Learn more about TLC Laser Eye Centers at www.tlcvision.com or by calling 1-888-225-5852.
About TLCVision
TLCVision is North America's premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality patient care. Through its centers management and technology access service models, and its managed care contracting strength, TLCVision maintains leading positions in Refractive and Cataract markets. More information about TLCVision can be found on the corporate website www.tlcv.com. Go to www.tlcvision.com for information on refractive surgery.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plans" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including the timing of expenditures, effects of competition, changes to pricing, acquisitions and expansion opportunities, any of which could cause actual results to vary materially from current results or TLCVision's anticipated future results. See the Company's reports filed with the Canadian Securities Regulators and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward looking statements. TLCVision assumes no obligation to update the information contained in this press release.
Contacts:
TLC Vision Corporation
Anna Austin
EVP, Corporate Communications
(636) 534-2271
Email: investor.relations@tlcvision.com
Website: www.tlcv.com / www.tlcvision.com
GENR 2.31 Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Jun 25, 2007 8:30:00 AM
PLYMOUTH MEETING, Pa., June 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that data from a preclinical study of trodusquemine (MSI-1436) for the treatment of obesity were presented during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz, Genaera research scientist and lead author of Abstract #1801-P, presented, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."
The poster presentation summarizes results from preclinical studies demonstrating that trodusquemine suppresses appetite and causes differential weight loss in a mouse model of diet-induced obesity (DIO). Data presented also indicates that trodusquemine selectively inhibits PTP-1B, an enzyme central to controlling the function of both the leptin and insulin pathways. In addition, trodusquemine was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model, making trodusquemine a promising therapeutic candidate.
"This preclinical data supports our current Phase 1 clinical strategy for trodusquemine as a treatment for obesity and further reinforces our belief that trodusquemine may also be successful in the treatment of type 2 diabetes," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We believe that, if successful, trodusquemine could be an effective monotherapy able to treat both obesity and type 2 diabetes, and could revolutionize the way these metabolic diseases are treated."
Scientists from Genaera will be available for discussion of the poster today from 12:00 p.m. to 2:00 p.m. Central Time in the Poster Hall at the conference.
For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&Men uID=100
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
About Trodusquemine (MSI-1436)
Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established, validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B), that is central to both insulin and leptin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment of two of the most serious metabolic diseases, obesity and type 2 diabetes. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to address co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquamine (or MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune for a second core program that is presently undergoing Phase 2 clinical testing. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
----------------------------------------------
Investors
Genaera Corporation
+1-610-941-5675; Media
Susan Neath of Porter Novelli Life Sciences
+1-609-529-0676
sneath@pnlifesciences.com
IAO .43 Global Hotline Moves Into Top Ten Japanese Outbound Telemarketing Companies
Jun 25, 2007 8:30:00 AM
SAN FRANCISCO, June 25 /PRNewswire-FirstCall/ -- IA Global, Inc. (Amex: IAO) announced today that its wholly owned subsidiary, Global Hotline, has now moved into the top ten of exclusively outbound telemarketing companies in Japan. Demonstrating the importance and potential of the company's previously announced expansion into the market research arena and the addition of its fifth call center which is expected to open in late July 2007, the company disclosed that its active database of companies has grown to exceed 7,000,000 and its database of households now exceeds 25,000,000. The company also disclosed that, each working day, its call centers generate more than 134,000 outbound telephone contacts. Upon achieving full staffing of the fifth call center total employee headcount is expected to reach 1,050 employees.
Hideki Anan, President of GHI, stated "Our goal is to break into the top five of exclusively outbound telemarketing companies in Japan in the near future and we further intend to continue to expand our client base and service offerings. The opportunity for foreign companies with products suitable to the Japanese market is expanding. We believe GHI is well positioned to assist those companies seeking to gain rapid market presence in Japan."
About IA Global, Inc.
IA Global, Inc. ("IA Global") is a strategic holding company with a dedicated focus on growth through mergers and acquisitions in the Pacific Rim region. Our mission is to identify and invest in business opportunities, apply our skills and resources to grow and enhance the performance of those businesses across all business metrics, and to deliver accelerating shareholder value.
To realize this plan, in fiscal 2007 the company is actively expanding investments in businesses in the consumer, technology, services, and health sectors, sectors with long-term growth prospects in which applying our skills and resources can add significant value to our investments. At the same time, the company is expanding its reach to encompass the Philippines/ Singapore, India, and China, and the outstanding growth opportunities and synergies these markets present.
In Japan, IA Global is 100% owner of Global Hotline, Inc., an operator of major call centers for telemarketing of telecommunications and insurance products. Since our acquisition of the Global Hotline, Inc. in June 2005, its business has expanded rapidly with the agreement of significant multi-year contracts with major corporations. With these revenues streams in place, revenues in 2007 are expected to double year on year.
In Australia, the Company has a 36% stake in Australian Secured Financial Limited and its affiliates, Australian Secured Investments Ltd, ADJ Services Pty Ltd. and Auslink Ltd (collectively, "ASFL") which raise funds through the issuance of debentures within Australia and provide short term, secured, real property loans to businesses and investors in Australia.
For further information, contact:
Investor Relations
IA Global, Inc.
101 California Street, Suite 2450
San Francisco, CA 94111
415-946-8828 (t)
415-946-8801 (f)
ir@iaglobalinc.com
www.iaglobalinc.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this report reflect the good faith judgment of our management and the statements are based on facts and factors as we currently know them. Forward- looking statements are subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Specifically, the comments concerning the profitability, revenue growth and potential new contracts of Global Hotline and target sectors and markets are forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements, as a result of either the matters set forth or incorporated in this report generally or certain economic and business factors, some of which may be beyond the control of IA Global. These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital to support our operations and projections of revenues and profitability for the significant contracts. Readers are urged not to place undue reliance on these forward-looking statements which speak only as of the date of this press release. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
SOURCE IA Global, Inc.
----------------------------------------------
Investor Relations
IA Global
Inc.
+1-415-946-8828
fax +1-415-946-8801
ir@iaglobalinc.com
ICOP 8.55 ICOP and Sprint to Exhibit at the International Association of Campus Law Enforcement Administrators' 49th Annual Conference
Jun 25, 2007 8:30:00 AM
LENEXA, Kan., June 25 /PRNewswire-FirstCall/ -- As part of its national joint marketing collaboration with Sprint (NYSE: S), ICOP Digital, Inc. (Nasdaq: ICOP), an industry-leading company engaged in advancing digital surveillance solutions, today announced the companies will be co-exhibiting at the International Association of Campus Law Enforcement Administrators' (IACLEA) 49th Annual Conference in Las Vegas, Nevada.
WHEN: Tuesday, June 26 -- Friday, June 29, 2007
WHERE: Exhibit Booth #315
Green Valley Ranch
2300 Paseo Verde Parkway
Henderson, Nevada
WHAT: ICOP and Sprint representatives will be available to discuss and
demonstrate ICOP LIVE(TM), a component of the ICOP Solution(TM)
that is enabled by the Sprint Mobile(R) Broadband Network,
optimized by EV-DO Revision A, the nation's largest wireless high
speed network. With ICOP LIVE, it is possible to optimize the
response, management and outcome of a crisis, security breach or
crime-in-process through the delivery of live streaming video,
providing real-time situational awareness -- delivered both to
first responder headquarters and to first responder vehicles --
without having to load special software on the receiving devices.
IACLEA is an association that advances campus public safety for its
more than 1,100 educational institution members and 1,900
individual professional members by providing educational resources,
advocacy, and professional development services.
The ICOP Solution is enabled by the Sprint Mobile(R) Broadband Network, optimized by EV-DO Revision A, the nation's largest wireless high speed network -- reaching more than 206 million people across the country. This solution delivers live streaming video and audio to and from first responder vehicles to their headquarters and Sprint smartphones, laptops and other web- enabled computing devices. In addition to live streaming video and audio, this solution provides access to critical documents, such as site maps, floor plans, and other relevant data (stored on the local site server), vital to first responders when responding to an incident. For the first time ever, digital surveillance solutions makes it possible to secure the people, assets and profits in the community, allowing first responders to optimize the management and outcome of any security breach, crisis situation or crime-in- progress. Never before has this level of community-centric surveillance and communications capability been possible.
For the past several weeks, ICOP and Sprint have been actively engaged in executing a national awareness campaign focused on marketing the ICOP Solution to both the public and private sectors, with a goal of promoting community- wide adoption of the technology for deployment in local first responder agencies, schools, banks, commercial and municipal buildings and government facilities. In addition to co-hosting discussions with numerous potential enterprise and government customers, ICOP and Sprint have been co-exhibiting at a series of emergency preparedness and law enforcement conferences held throughout the country, including:
-- New Jersey Emergency Preparedness Conference, held in Atlantic City,
New Jersey on May 7-11, 2007;
-- New York State Emergency Preparedness and Security Conference and Expo,
held in Albany, New York on May 21-22, 2007;
-- New England Emergency Preparedness Conference, held in Boston,
Massachusetts on May 29-30, 2007;
-- IACP 31st Annual Law Enforcement Information Management Training
Conference and Exhibition, held in Greensboro, North Carolina on May
21-25, 2007; and
-- Cincinnati Emergency Preparedness Conference, held in Cincinnati, Ohio
on May 10, 2007.
"We are very encouraged by the growing awareness and strong interest being generated for our novel ICOP Solution as a result of our collaborative marketing efforts with Sprint," stated Dave Owen, Chairman and CEO of ICOP Digital. "It is evident that first responder agencies and corporate leaders are beginning to recognize and appreciate how the ICOP Solution can provide the greatest possible level of situational awareness and real-time intelligence during a crisis, security breach or crime-in-progress, thus helping to optimize immediate response and promoting positive outcomes."
About ICOP Digital, Inc.
ICOP Digital, Inc. protects people, assets and profits, providing a Veil of Protection(TM) for our nation's communities with innovative, mission- critical security, surveillance and communication solutions. The Company engineers, manufactures and markets mobile and stationary surveillance products for use in the public and private sectors, and facilitates the delivery of live video to first responders. The ICOP Model 20/20(R), ICOP's flagship product, is the leading digital in-car video recorder system for law enforcement. The ICOP Guardian(TM) is a stationary IP camera that records high quality video images on a local server, and is capable of activation through several triggers. ICOP LIVE(TM) delivers live streaming video to and from first responder vehicles and headquarters, empowering first responders with enhanced situational awareness, helping to optimize the outcome of a crisis. (GSA Contractor)
For more information, please view the following video presentations at http://www.icopdigital.com/why_icop.html and www.ICOP.com/veil.html, or visit www.ICOP.com.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission.
For more information, contact:
Laura E. Owen, President and COO
16801 West 116th Street
Lenexa, KS 66219 USA
Phone: (913) 338-5550
Fax: (913) 312-0264
Lowen@ICOP.com
www.ICOP.com
For Investor Relations:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO
Phone: (407) 585-1080
ICOP@efcg.net
SOURCE ICOP Digital, Inc.
----------------------------------------------
Laura E. Owen
President and COO
ICOP Digital
Inc.
+1-913-338-5550
Fax
+1-913-312-0264
Lowen@ICOP.com; or Dodi Handy
President and CEO
Elite Financial Communications Group
LLC
+1-407-585-1080
ICOP@efcg.net
for ICOP Digital
Inc.
PTEC 8.00 Phoenix Technologies Embeds SecureCore Firmware in Lenovo PCs
Jun 25, 2007 8:30:00 AM
MILPITAS, Calif., June 25 /PRNewswire-FirstCall/ -- Phoenix Technologies Ltd. (Nasdaq: PTEC), the global leader in core systems firmware, today announced a two-year agreement with leading computer manufacturer Lenovo to license Phoenix SecureCore as the secure firmware foundation for its ThinkPad notebook and ThinkCentre M Series desktop PCs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/SFTU048LOGO )
"With a longstanding reputation for quality, Lenovo continues to set the standard in the industry for durability, reliability and productivity by introducing recent innovations like a Top Cover Roll Cage, a new cooler and quieter design and Battery Stretch for extra computing time on our ThinkPad notebooks," said Peter Hortensius, senior vice president, Notebook Business Unit, Lenovo. "Phoenix SecureCore complements our focus on excellent design by providing the latest, secure firmware, an essential component in a notebook computing environment."
Built on the solid foundation of Phoenix Technologies' long term leadership in core system engineering, SecureCore is the most advanced and secure firmware that has been validated for the newest Intel mobile chipsets and offers full support for the latest EFI and UEFI specifications. As a result, SecureCore delivers the most efficient interface between a device's operating system and the platform firmware. SecureCore features advanced pre- boot authentication and embedded cryptography, and also includes integrated biometric and smartcard capabilities.
"Phoenix SecureCore allows OEMs to reduce their time to market, while enhancing performance and security on their notebooks and desktop PCs," said Dave Gibbs, senior vice president and general manager, Worldwide Field Operations at Phoenix Technologies. "We are extremely pleased to further expand on our long term relationship with Lenovo and to work with them on all their new mobile products for the next two years," he added.
About Phoenix Technologies
Phoenix Technologies Ltd. (Nasdaq: PTEC) is the global market leader in system firmware that provides the most secure foundation for today's computing environments. The Company established industry leadership with its original BIOS product in 1983, and today has 154 technology patents, has shipped in over one billion systems, and continues to ship in over 125 million new systems each year. The company's breakthrough solution, SecureCore, enables hardware vendors to bring secure devices to market with the latest advances in Microsoft operating systems. The PC industry's top builders and specifiers trust Phoenix to pioneer open standards and deliver innovative solutions to help them accelerate time to market, differentiate products and increase profits. Phoenix is headquartered in Milpitas, California with offices worldwide. For more information, visit http://www.phoenix.com. Phoenix, Phoenix Technologies, and the Phoenix Technologies logo are trademarks and/or registered trademarks of Phoenix Technologies Ltd. All other trademarks are the property of their respective owners.
Safe Harbor
The statements in this release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, Lenovo continuing to license Phoenix products. These statements involve risk and uncertainties, including: our ability to successfully enhance existing products and develop and market new products and technologies; variations in demand for digital devices; the ability of Lenovo and other customers to introduce and market new products that incorporate our products; failure to protect our intellectual property rights; changes in our relationship with leading software and semiconductor companies; and product and price competition in our industry. For a further list and description of risks and uncertainties that could cause actual results to differ materially from those contained in the forward looking statements in this release, we refer you to the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this release are based upon assumptions, forecasts and information available to the Company as of the date hereof, and the Company assumes no obligation to update any such forward- looking statements.
Contacts:
Media & Analyst Relations:
Phoenix Technologies
Global Communications
Tel. +1 408 570 1946
E-mail: public_relations@phoenix.com
Scott Vansickle, Global Fluency
Tel. +1 650 433 4222
E-mail: svansickle@globalfluency.com
Investor Relations:
Erica Mannion, Sapphire Investor Relations
Tel. +1 212 766 1800 x3
Investor_relations@phoenix.com
SOURCE Phoenix Technologies Ltd.
----------------------------------------------
Media & Analyst Relations: Phoenix Technologies Ltd.
Global Communications
+1-408-570-1946
public_relations@phoenix.com or Scott Vansickle of Global Fluency
+1-650-433-4222
svansickle@globalfluency.com
for Phoenix Technologies Ltd.; Investor Relations: Erica Mannion
Sapphire Investor Relations
+1-212-766-1800 x3
Investor_relations@phoenix.com
for Phoenix Technologies Ltd.
ATML 5.70 Atmel's New secureAVR Microcontroller Targets Banking SDA Market and Small ID Programs
Jun 25, 2007 8:30:00 AM
ROUSSET, France, June 25 /PRNewswire/ -- Atmel(R) Corporation (Nasdaq: ATML), announced today the introduction of its AT90SC9604RU secure microcontroller in replacement of its present AT90SC6404RT chip. The additional ROM memory in the device allows customers to implement sophisticated applications such as CPA (Common Platform Application) for the EMV banking, SDA (Static Data Authentication) market and makes this chip perfectly suited for cost sensitive applications such as low end contact bank cards.
Based on Atmel's optimized 8-/16-bit RISC SecureAVR(R) CPU architecture, the AT90SC9604RU features on-chip high density, compact memories: 4 Kbytes EEPROM, 96 Kbytes of user-ROM, and 2 Kbytes of RAM. This product has been designed to meet the security standards of Common Criteria EAL4+ and EMVCo. It shares the same common features with Atmel's secureAVR family including strong security mechanisms, a DES/TDES processor, a true random number generator, DFA/DPA/SPA resistant, firewalls and environmental protections to name just a few.
Benoit Makowka, Banking and ID Product Line Manager stated, "The addition of this new device reinforces Atmel's commitment to serve banking and government markets. We strongly believe that this new product will help our customers to develop compact Operating Systems and application code to serve in long term a cost sensitive market requiring more and more security."
Availability and Pricing
AT90SC9604RU samples are available now. Production will start in Q2 of 2007. Pricing starts at US $0.67 for 10k units.
About Atmel
Atmel is a worldwide leader in the design and manufacture of microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets.
Atmel(R), logo and combinations thereof, secureAVR(R) and others, are registered trademarks or trademarks of Atmel Corporation or its subsidiaries. Other terms and product names may be trademarks of others.
Information:
Atmel's AT90SC9604RU product information may be retrieved at http://www.atmel.com/dyn/products/product_card.asp?part_id=4147
For further information on the SecureAVR family, go to http://www.atmel.com/products/SecureAVR/
Press Contacts:
Carine Bourgon, Communications Manager - Rousset
Phone: (+33) 4 42 53 60 52, Email: carine.bourgon@rfo.atmel.com
Helen Perlegos, Public Relations - USA and Asia Pacific Rim
Phone: (+1) 408 487-2963, Email: hperlegos@atmel.com
Veronique Sablereau, Corporate Communications Manager - Europe
Phone: +33 1 30 60 70 68, Fax: + 49 71 31 67 24 23
Email: veronique.sablereau@atmel.com
SOURCE Atmel Corporation
----------------------------------------------
Carine Bourgon
Communications Manager - Rousset
(+33) 4 42 53 60 52
carine.bourgon@rfo.atmel.com
or Helen Perlegos
Public Relations - USA and Asia Pacific Rim
+1-408-487-2963
hperlegos@atmel.com
or Veronique Sablereau
Corporate Communications Manager - Europe
+33 1 30 60 70 68
fax
+49 71 31 67 24 23
veronique.sablereau@atmel.com
all of Atmel Corporation
NTWK 1.58 NetSol Technologies to Offer IT Outsourcing and Customized Development Services to North American Equipment and Finance Market
NetSol McCue, the Company's North America Division to Commence Rollout of IT Outsourcing and Customized Development Services
Jun 25, 2007 8:30:00 AM
CALABASAS, CA -- (MARKETWIRE) -- 06/25/07 -- NetSol Technologies, Inc. ("NetSol") (NASDAQ: NTWK), a multinational provider of enterprise software and IT services to the financial services industry, announced that NetSol McCue, the company's North American division has commenced the rollout of a full suite of IT outsourcing services and customized development solutions to the North American equipment finance technology market. NetSol's North America division will offer a range of IT services and resources, leveraging 30 plus years of equipment leasing and lending experience.
John McCue, president of NetSol North America, comments, "Our domain expertise within the equipment, vehicle, and captive finance industry is a key differentiator as compared with more generic offshore development providers. NetSol's North American services team will provide a cost-effective blend of onshore LeasePak expertise closely integrated with the offshore capabilities of our CMMi Level 5 certified resources based in Lahore. NetSol Technologies will be able to hit the ground running in any equipment or vehicle finance IT operation in North America. We believe this accelerated path to positive ROI will be a strategic advantage for our customers."
The NetSol McCue services team managing the offering has completed over 100 implementations to date in both equipment and vehicle leasing organizations, including Volkswagen Credit, Key Bank, Bank of Tokyo Mitsubishi, Cisco, and Yamaha Motor Corp.
While the division's Client Consulting Services department has long offered NetSol McCue customers a range of business process engineering services, the new offering package will greatly expand the menu of available services to meet market needs. New services to be offered will include customized application development, a full range of Quality Assurance (QA) services, customized strategic report design, and dashboard tool development for users of the division's flagship application, LeasePak 6.0 Enterprise Edition.
NetSol Technologies CEO Najeeb Ghauri stated, "IT service and outsourcing is estimated to be a $500 billion market in North America. From the very beginning, it has been our vision and goal for NetSol-McCue to capture part of the IT outsourcing and services market from within its core leasing and finance expertise." Mr. Ghauri concluded, "We are confident that this focused offering will receive an excellent reception in the North American equipment finance technology market. We already have a strong track record of achievement in delivering outsourced IT services and solutions to the North American insurance industry. I am confident that NetSol Technologies will be able to show similar success in the North American based leasing and lending organizations, from both within our existing customer base as well as with new prospects."
About NetSol Technologies
NetSol Technologies is a multinational provider of enterprise software and IT services to the financial services industry. NetSol helps clients to identify, evaluate and implement technology solutions to meet their strategic business challenges and maximize their bottom line. By utilizing its worldwide resources, NetSol delivers high-quality, cost-effective equipment and vehicle finance portfolio management solutions. The Company also delivers managed IT services ranging from consulting and application development to systems integration and development outsourcing. NetSol's commitment to quality is demonstrated by its achievement of both ISO 9001 and SEI (Software Engineering Institute) CMMi (Capability Maturity Model Integration) Level 5 assessment, a distinction shared by only 94 companies worldwide. The Company's clients include global automakers, financial institutions, technology companies and governmental agencies. NetSol's largest customer, DaimlerChrysler Services, ranks the Company as a preferred vendor in more than 40 countries. Headquartered in Calabasas, CA, NetSol Technologies also has operations and/or offices in London, San Francisco, Adelaide, Beijing, Lahore and Karachi, Pakistan. To learn more about NetSol Technologies, visit the Company's web site at www.netsoltek.com. Click here to join the NetSol Technologies, Inc. email distribution list: http://www.b2i.us/irpass.asp?BzID=897&to=ea&s=0.
Forward-Looking Statements
This press release may contain forward-looking statements relating to the development of the Company's products and services and future operation results, including statements regarding the Company that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "anticipate," "intend," variations of such words, and similar expressions, identify forward-looking statements, but their absence does not mean that the statement is not forward looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include the progress and costs of the development of products and services and the timing of the market acceptance.
Contacts:
NetSol Technologies, Inc.
Tina Gilger
Chief Financial Officer
Tel: +1 818-222-9195, x112
Investor Relations
Christopher Chu
The Global Consulting Group
Tel: +1-646-284-9426
Email: cchu@hfgcg.com
CYTR 3.55 CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
Safety and tolerability results support a higher arimoclomol dose for planned Phase IIb efficacy clinical trial for ALS
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising multiple dose clinical trial in healthy volunteers with its drug candidate arimoclomol. CytRx believes that the results of this trial support the use of arimoclomol in future clinical trials, including its ALS Phase IIb clinical trial, at doses up to six-fold higher than that used in its previous Phase IIa clinical trials for ALS.
CytRx plans to begin its Phase IIb clinical trial in the second half of this year, subject to U.S. Food and Drug Administration (FDA) clearance. As previously announced, this trial, planned to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites, was designed to monitor changes in the progression of disease symptoms and would be completed about 18 months after the beginning of patient enrollment. Following consultation with the FDA, CytRx is now considering various options, including increasing the size and duration of the planned trial and/or conducting a second efficacy clinical trial for ALS, possibly in parallel with the Phase IIb trial, to provide additional data to support a possible approval decision by the FDA.
CytRx expects to announce results of its recently-completed six-month open-label extension trial with arimoclomol for ALS later this week.
"It is rewarding to see significant progress toward our goal of initiating the Phase IIb clinical trial for arimoclomol this year," stated CytRx's President and CEO Steven A. Kriegsman. "Based on the results of this clinical trial we plan to proceed with a dose that is four times greater than that used in our previous Phase IIa ALS clinical trials. These study results will help us optimize trial design to maximize our chances of demonstrating efficacy and supporting our commitment to help those who suffer from the devastating effects of ALS."
The double-blind, placebo-controlled rising multiple dose study, which was announced in February 2007, was designed to identify the highest safe and well-tolerated arimoclomol dose. Forty healthy volunteers were divided evenly into groups of 10 subjects. In each group three subjects received a placebo capsule without drug and seven received arimoclomol at either 100 mg (the highest dose provided in the Phase IIa double-blind and open-label extension studies), 200 mg, 400 mg, or 600 mg three times daily over a seven day period. Dose escalation proceeded carefully, with safety and tolerability demonstrated at lower dose levels prior to testing higher doses. The study indicated that all four doses were safe and well-tolerated. Based on these results and additional data, CytRx plans to proceed with a 400 mg dose of arimoclomol three times daily in its planned Phase IIb efficacy trial.
"While these results indicate that we could potentially use an even higher dose of arimoclomol, we selected 400 mg for our upcoming efficacy trial for several reasons," said Jack Barber, Ph.D., CytRx's Chief Scientific Officer. "First, the 400 mg dose resulted in drug serum exposures higher than those that have provided maximum therapeutic benefit in animals. Second, using less than the highest possible dose potentially provides a margin of safety for ALS patients. Finally, larger doses may not be practical in this population as the capsules could be too large for ALS patients who sometimes have difficulty swallowing."
CytRx is presently conducting a follow-up clinical trial in healthy volunteers to provide longer-term safety and tolerability information at the 400 mg dose. This double-blind, placebo-controlled study includes 16 healthy volunteers: four are receiving a placebo capsule without drug and 12 are receiving 400 mg of arimoclomol three times daily for 28 days. The results of this safety study will be reported early in the fourth quarter of this year, prior to the planned initiation of the Phase IIb efficacy trial.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS and has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.
About RXi Pharmaceuticals Corporation
Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding regulatory approvals for future clinical testing of arimoclomol, including CytRx's planned Phase IIb clinical trial, and the scope of the clinical testing that may be required by regulatory authorities for arimoclomol, uncertainties regarding the timing and amount of revenues, if any, that will be realized by CytRx from the commercialization of arimoclomol, the significant time and expense that will be incurred in developing any of the potential commercial applications for arimoclomol and the potential need for additional capital to fund the development of arimoclomol, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: CytRx Corporation
----------------------------------------------
CytRx Corporation
CEOcast
Inc.
Dan Schustack
212-732-4300
dschustack@ceocast.com
XNL 1.52 Xethanol Announces Appointment of Thomas Endres to Chief Operating Officer
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
Xethanol Corporation (XNL), a renewable biofuels company, today announced that Thomas J. Endres has been appointed Chief Operating Officer of the company. Mr. Endres has served as Xethanol's Executive Vice President, Operations since March 15, 2007 and will retain his title as Executive Vice President.
Mr. Endres commented: "I am honored the Board of Directors has expressed its confidence in me. I look forward to continuing to work with the Board and the senior management team and am excited about the company's future in the alternate energy sector."
Mr. Endres, age 50, joined Xethanol as Senior Vice President, Operations on September 7, 2006. Before joining the company, Mr. Endres served in the United States Army for 26 years, retiring with the rank of Lieutenant Colonel. From August 1997 until August 2006, he served as Director of Operations/Director of Cadet Activities at the United States Military Academy at West Point, from which he graduated in 1980. In this position, he was responsible for managing $2 billion in facilities, a $50 million budget and 356 employees. From November 1999 through April 2002, Mr. Endres also served as a member of the board of directors of the West Point Federal Credit Union, which managed over $55 million in funds.
David Ames, President and CEO of Xethanol, said: "Tom Endres has distinguished himself at Xethanol just as he did during his impressive military career in operations and management. Tom is a key asset to us at Xethanol as the company moves forward in renewable energy."
Throughout his military career, Lt. Colonel Endres (Ret.) held various other operational posts from which he oversaw the management, logistics and implementation of physical and manpower assets. He was the Chief of Special Operations for the Aviation Management Office where he was responsible as Human Resources Officer for over 10,000 US Army pilots. He also served as operations officer for the 4th Aviation Battalion, 4th Infantry Division, overseeing training and operations of a 400-person unit with $1.2 billion in assets.
About Xethanol Corporation
Xethanol Corporation is a renewable energy company focused on alternate energy products and technologies as well as producing ethanol and other co-products. The company is developing and executing a multi-pronged business strategy:
-- a technology strategy in which it works with leading
scientists to license, acquire and commercialize innovative
technologies in alternate energy;
-- a production strategy in which it owns and plans to develop
ethanol and gasification plants; and
-- an investment strategy in which it owns and seeks to acquire
majority or minority positions in alternative energy
businesses that include Advanced Biomass Gasification
Technologies, Inc., which holds patents and know-how related
to lignin and biomass gasification, and H2Diesel Holdings,
Inc., a development stage company that holds an exclusive
license for North America, Central America and the Caribbean
to proprietary technology for the manufacture of an
alternative biofuel.
For more information about Xethanol, please visit its website at http://www.xethanol.com.
Source: Xethanol Corporation
----------------------------------------------
ICR
Kathleen Heaney
203-803-3585
ir@xethanol.com
ARBA 9.68 Ariba Launches Podcast for Chief Financial Officers
Session discusses need for link between finance and procurement to improve business performance
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
SUNNYVALE, Calif.--(BUSINESS WIRE)--
Ariba, Inc. (Nasdaq: ARBA), the leading spend management solutions provider, today launched a podcast designed to help chief financial officers, vice presidents of finance and controllers understand how by working with procurement, they can advance in the battle to control costs and improve business performance. Available through Supply & Demand Chain Executive Magazine at www.sdcexec.com, the podcast discusses the results of a recent survey conducted by CFO Research Services sponsored by Ariba which shows that procurement is a key ally when it comes to lowering costs and enhancing business unit decision making, planning, budgeting and forecasting.
"Traditionally, there has been a gulf between finance and procurement," said Paul Tong, Senior Product Manager, Ariba. "Leading finance executives are realizing that in order to achieve their objectives, they must bridge this gap. Financial systems such as ERP can automate routine transaction processing and reporting functions. But they cannot provide timely and accurate information on spend that is needed to support strategic initiatives. Procurement has this information and with the right solutions and processes, finance can access and leverage it to their advantage."
Last month, Ariba unveiled the results of a survey of senior finance executives at companies throughout North America, conducted on its behalf by CFO Research Services. The survey, "CFOs Views on Procurement-Information, Risk and Money," provides an in-depth look at how CFOs view procurement, as well as their thoughts on the role that procurement can play in helping them achieve their goals. Among the key findings:
-- When seeking to control costs, executives see the greatest
opportunity in managing spending on direct materials and
indirect goods and services, sourcing through preferred
vendors and improving their interactions with suppliers.
-- Most companies are unable to gather timely and accurate
information on purchasing activities and consequently have
poor visibility into their spending.
-- Organizations that have adopted and implemented
technology-based solutions report greater satisfaction with
and better information from their procurement functions.
"Controlling costs is something that all companies struggle with, regardless of their size or the industry they operate in," Tong continued. "But by looking beyond large scale transactional systems that fail to provide consolidated and forward-looking views into spend and forging a strong partnership between finance and procurement, they can succeed."
Ariba provides a comprehensive range of solutions that combine market-leading technology with deep category expertise and industry best-practices to help companies manage their spend from end-to-end. Flexible and easy to use, Ariba's solutions seamlessly integrate with all major ERP systems and enable companies to understand their spending patterns, identify opportunities for savings, and design and execute strategies to get them to the bottom line.
To learn more about Ariba(R) Spend Management(TM) solutions and the benefits these solutions are delivering to companies around the world, please visit: www.ariba.com
To download a complete copy of "CFOs Views on
Procurement-Information, Risk and Money," visit:
http://www.ariba.com/learningcenter/view_page.cfm?asset_id=347
About Ariba, Inc.
Ariba, Inc. is the leading provider of spend management solutions to help companies realize rapid and sustainable bottom line results. Successful companies around the world in every industry use Ariba Spend Management(TM) software and services. Ariba can be contacted in the U.S. at 1.650.390.1000 or at www.ariba.com.
Copyright (C) 1996 - 2007 Ariba, Inc.
Ariba, the Ariba logo, AribaLIVE and SupplyWatch are registered trademarks of Ariba, Inc. Ariba Spend Management, Ariba Spend Management. Find it. Get it. Keep it., Ariba. This is Spend Management, Ariba Solutions Delivery, Ariba Analysis, Ariba Buyer, Ariba Category Management, Ariba Category Procurement, Ariba Contract Compliance, Ariba Contracts, Ariba Contract Management, Ariba Contract Workbench, Ariba Data Enrichment, Ariba eForms, Ariba Electronic Invoice Presentment and Payment, Ariba Invoice, Ariba Sourcing, Ariba Spend Visibility, Ariba Travel and Expense, Ariba Procure-to-Pay, Ariba Workforce, Ariba Supplier Network, Ariba Supplier Connectivity, Ariba Supplier Performance Management, Ariba PunchOut, Ariba QuickSource, PO-Flip, Ariba Settlement, Ariba Spend Management Knowledge Base, Ariba Ready, Ariba Supply Lines, Ariba Supply Manager, Ariba LIVE and It's Time for Spend Management are trademarks or service marks of Ariba, Inc. Ariba Proprietary and Confidential. All rights reserved. Patents pending. All other trademarks are property of their respective owners.
Ariba Safe Harbor
Safe Harbor Statement under the Private Securities Litigation Reform Act 1995: Information and announcements in this release involve Ariba's expectations, beliefs, hopes, plans, intentions or strategies regarding the future and are forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Ariba as of the date of the release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to Ariba's operating and financial results to differ materially from its current expectations include, but are not limited to: delays in development or shipment of new versions of Ariba's products and services; lack of market acceptance of Ariba's existing or future products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; the ability to attract and retain qualified employees; difficulties in assimilating acquired companies; long and unpredictable sales cycles and the deferrals of anticipated orders; declining economic conditions; inability to control costs; changes in the company's pricing or compensation policies; significant fluctuations in our stock price; the outcome of and costs associated with pending or potential future regulatory or legal proceedings; the impact of our acquisitions, including the disruption or loss of customer, business partner, supplier or employee relationships; and the level of costs and expenses incurred by Ariba as a result of such transactions. Factors and risks associated with its business, including a number of the factors and risks described above, are discussed in Ariba's Form 10-Q filed May 9th, 2007.
Source: Ariba, Inc.
----------------------------------------------
Ariba
Inc.
Karen Master
412-297-8177
kmaster@ariba.com
TKO 1.76 EthoStream Expands Reseller Program into Canada; Newest Reseller Electro Tel Installs HSIA in 20 Hotels
EthoStream's High Speed Internet Access (HSIA) System Installed in 200 Hotels in Canada
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
GERMANTOWN, Md.--(BUSINESS WIRE)--
EthoStream, LLC, a Telkonet company (AMEX:TKO), operators of one of the largest hospitality high-speed Internet access (HSIA) networks in the U.S., and a preferred or endorsed provider for some of the world's largest hotel franchisors, has signed Electro Tel, a full-service communications and security provider based in Alberta, Canada, to market its high-speed Internet access system throughout Canada. Electro Tel, who became an EthoStream reseller in January 2007, has installed EthoStream's system, providing both wired and wireless broadband Internet access, in 20 properties to-date, including Ramada, Best Western, Super 8 and Travelodge.
James MacKay, Sales Manager and TELUS Representative of Electro Tel, explains, "We selected EthoStream on the strength of their marketing strategies and robust service offering. Upon comparing EthoStream to all other competitors on the basis of service level offerings, pricing and leadership, combined with their exclusive Remote Management Console and on-going property management, the choice was clear, with EthoStream winning hands down. No other HSIA vendor came close.
"One of the highlights of working with EthoStream is their willingness to work with a wide variety of equipment which makes the installation a simple integration of the EthoStream Server with the property's existing hardware. In this scenario, the installation and testing, along with educating the staff, often takes less than four hours on site.
"EthoStream is very approachable, right up to the CEO level, and are all committed to the spirit of partnership in getting the solutions into the client's properties and in maintaining a high level of customer satisfaction on an ongoing basis. They are the only company I am aware of that offers full-disclosure to the client in the form of their on-line web-based Remote Management Console (RMC). With the RMC, anyone with a username and password has access to reports, including system up-time, bandwidth, the number of users, user history, phone/Internet support trouble tickets and the end result of each. Time and again, this illustrates the value in the EthoStream solution and also serves as a measuring stick which can provide an important piece of mind for a hotel owner."
About Electro Tel
Electro Tel is a full-service communications and security provider based in Alberta, Canada with coverage province-wide also including parts of British Columbia and Saskatchewan. We have partnerships with TELUS, NEC, Toshiba, Microsoft, HP, EthoStream, Nortel Networks, Voxcom, GE and many others. We sell, install and service, TELUS cellular phones, TELUS wireline telecommunications and data services, Hi-speed networks, telephone systems, security systems, surveillance equipment, photocopier and imaging equipment, computers, wireless data and 2-way radios. We don't consider anything "sold" until after it is installed and working to the customer's satisfaction. We promise 24x7x365 service response and are committed to having a technician troubleshooting a reported problem within 15 minutes from time of call. For more information, visit www.electro-tel.com.
About EthoStream
EthoStream, LLC is a technology solution provider targeting the hospitality and MDU/MTU verticals. Operating one of the largest hospitality high-speed Internet access (HSIA) networks in the U.S., EthoStream is a preferred or endorsed provider for some of the world's largest hotel franchisors. Now offering solutions including VOD, VoIP, digital video surveillance, Internet connectivity and HSIA packages, EthoStream has developed the most comprehensive technology management platform available for the hospitality industry.
EthoStream has distanced itself from other providers in the hospitality HSIA field through the size of its EthoStream Hospitality Network, high quality of technology and support provided to network members, security of the network and overall guest satisfaction. Beyond claims made by competitors, as the premier hospitality HSIA provider, EthoStream has continued to lead the industry through end-to-end service and its high quality standards. To learn more about EthoStream's products, services and EthoStream Hospitality Network, please visit http://www.ethostream.com.
About Telkonet
Telkonet develops and markets technology for the high-speed transmission of secure voice, video and data communications over in-premise and shipboard electrical wiring. The revolutionary Telkonet iWire System utilizes proven powerline communications (PLC) technology to deliver commercial high-speed broadband access from an IP "platform" that is easy to deploy, reliable and cost-effective by leveraging a building's existing electrical infrastructure. Telkonet's products are designed for use in commercial and residential applications, including multi-dwelling units and the hospitality and government markets. Applications supported by the Telkonet "platform" include but are not limited to: VoIP telephones, Internet connectivity, local area networking, video teleconferencing, IP surveillance, energy management and a host of other IT services. For more information, please visit www.telkonet.com.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's Registration Statement and in its Reports on Forms 8-K filed with the Securities and Exchange Commission (SEC).
Source: EthoStream, LLC
----------------------------------------------
Porter
LeVay & Rose
Inc.
Michael Porter
President
212-564-4700
mike@plrinvest.com
www.plrinvest.com
or
Rubenstein Public Relations
Adam Mazur
212-843-8073
amazur@rubensteinpr.com
MIPI 10.02 Molecular Insight Pharmaceuticals, Inc. Initiates First of Two Planned Pivotal Registration Trials for Zemiva(TM) in Detection of Cardiac Ischemia
- Estimated 600 to 700 Patient Phase 2 Trial to Assess Zemiva in Emergency Department Setting -
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a Phase 2 trial with Zemiva(TM) (iodofiltic acid I 123 or BMIPP) for the diagnosis of cardiac ischemia, or lack of sufficient blood supply to an area of the heart, in patients with suspected Acute Coronary Syndrome (ACS) in the emergency department setting. Zemiva is a metabolic, molecular imaging pharmaceutical that has previously demonstrated the ability to detect cardiac ischemia up to 30 hours after an ischemic event as compared to currently available techniques, which are limited to an approximate two hour imaging window. The current trial is designed to be a pivotal registration trial that, upon replication in a successive confirmatory Phase 3 trial, could form the basis of an application with the U.S. Food and Drug Administration (FDA) for marketing approval. Molecular Insight expects to report top line data from this trial in the second half of 2008.
"We are very pleased to have begun enrolling patients in Zemiva's pivotal clinical trial. This important milestone reflects the substantial progress we have made in building and advancing our pipeline of molecular imaging pharmaceuticals and targeted radiotherapeutics," said David S. Barlow, Chairman and Chief Executive Officer of Molecular Insight. "Imaging chest pain patients with Zemiva in the emergency department setting exemplifies the compelling potential of molecular imaging to provide patients and the healthcare system with significant medical and economic benefits."
"Patients who arrive in the emergency department complaining of chest pain may in fact be exhibiting symptoms of ACS, such as unstable angina or even myocardial infarction, and rapid treatment is essential because it significantly improves the outcomes for these patients," said Dr. John M. Mahmarian, Director of Nuclear Cardiology at Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas. "However, timely treatment depends on rapid and accurate diagnosis, and currently available diagnostic tools can require many hours or days to triage patients. This delays treatment for those who have ACS and places a significant burden on hospital resources to rule out the majority of patients whose pain is not cardiac-related. This trial with Zemiva will evaluate the potential of a molecular imaging pharmaceutical to rapidly identify ACS patients, including those whose chest pain symptoms may have subsided up to 24 hours earlier."
The trial, which is expected to involve an estimated 600 to 700 patients at up to 70 centers in the United States and Canada, is an open-label study with patients serving as their own control. The primary objective is to evaluate the ability of Zemiva to accurately identify myocardial ischemia in patients who present to the emergency department with suspected ACS. Because of the ability of Zemiva to detect "ischemic memory," patients can be evaluated in the trial if they experienced chest pain within the previous 24 hours, a timeframe which is not realistic with currently available techniques, such as perfusion imaging. The secondary objective of the trial is to confirm the safety of a single injection of Zemiva in patients suspected of myocardial ischemia related to ACS as reported in previous trials.
"In previous clinical studies, we have evaluated the safety of Zemiva, its ability to provide a 30-hour window for imaging cardiac ischemia once a patient's chest pain has subsided and the initial feasibility of imaging suspected ACS patients," said John W. Babich, Ph.D., President and Chief Scientific Officer of Molecular Insight. "Our expectations are that this trial will generate pivotal data for the future marketing registration of Zemiva by defining its potential to detect cardiac ischemia in a real world clinical setting."
The study will compare the ability of Zemiva to detect cardiac ischemia against the current standard of care for ACS. Patients will enter the study and will be stratified by high, moderate or low probability of ACS based on current triage procedures, such as medical history, initial ECG and cardiac troponin markers. They will then be imaged with Zemiva. Results of the Zemiva scans will be compared to the initial clinical impression as well as the final clinical diagnosis at the time of the patient's discharge. The clinical diagnoses will be made by two independent committees: an initial diagnosis committee that will review all data available for diagnosis from time of admission into the emergency department to four hours afterwards, and a final diagnosis committee that will review additional patient outcome data collected for 30 days after the patient leaves the hospital. The 30 day clinical outcomes data will be used as the established "truth standard" diagnosis of ACS and will serve as the comparator benchmark for trial analysis.
About Zemiva and ACS
Every year, approximately five to eight million patients enter emergency rooms in the United States with suspected acute coronary syndrome (ACS). Almost three million of these patients are admitted to the hospital for diagnosis, but only approximately 15 percent are ultimately determined to have ACS. In addition, approximately 25 percent of chest pain patients are discharged from the emergency department without having been diagnosed with ACS or admitted for further assessment, but one to five percent actually have ACS. Zemiva may provide the opportunity to improve disease management by rapidly identifying patients with ACS; reducing the number of missed diagnoses among discharged patients who experience a heart attack soon afterwards; and reducing hospitalization costs by quickly ruling out patients whose condition is not due to ischemia.
Zemiva is a fatty acid analog also known as 123I-BMIPP that detects cardiac ischemia by revealing abnormalities in the fatty acid metabolism of the heart. Under normal conditions, 70 percent to 80 percent of the energy for the heart is produced by the metabolism of fatty acids. However, in ischemic conditions where there is a lack of oxygen, fatty acid metabolism is drastically reduced and carbohydrates become the heart's primary energy source. This shift in metabolic activity persists for some time, and the phenomenon, called ischemic memory, can be imaged with Zemiva up to 30 hours after chest pain has subsided.
Molecular Insight has conducted four U.S. clinical trials with Zemiva, a Phase 1 study and three Phase 2 trials, including a Phase 2 clinical trial to develop a reference database of normal Zemiva images of the heart using SPECT imaging. The BMIPP molecule is approved in Japan and has been used in over 500,000 patients.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Azedra(TM), Onalta (TM), Zemiva(TM) and any other statements relating to product candidates, product development programs the FDA or clinical trial process including the commencement, process or completion of clinical trials or the regulatory process or the estimated number of patients and centers involved in the Zemiva trial. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Source: Molecular Insight Pharmaceuticals, Inc.
----------------------------------------------
Molecular Insight Pharmaceuticals
Inc.
Priscilla Harlan
617-492-5554
Vice President
Corporate Communications & Investor
Relations
MWY 6.45 Hour of Victory(TM) Arrives As Midway Ships Cinematic World War II First-Person Shooter
Console-Exclusive Xbox 360(TM) Title Available in Stores Now
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
CHICAGO--(BUSINESS WIRE)--
Midway Games Inc. (NYSE:MWY), a leading interactive entertainment industry publisher and developer, today announced that Hour of Victory(TM), the highly-anticipated World War II first-person shooter now exclusively for Xbox 360(TM), has shipped to retailers nationwide.
"Hour of Victory gives gamers a chance to play a World War II game the way they want - whether as a guns-blazing Commando, a stealthy covert-operative, or a sharpshooting Ranger," said Steve Allison, chief marketing officer, Midway. "Built using Unreal(R) Engine 3.0, Hour of Victory delivers high-action moments throughout, both in the single-player campaign or with the three different multiplayer modes over Xbox Live."
Hour of Victory allows gamers to play a key role in the pivotal and cinematic battles from the European and North African theaters of World War II, using the skills and gameplay style they choose. Sneak into enemy territory as a covert operative, storm the gates as a British Commando, or snipe from afar as an Army Ranger - each character's unique attributes will be needed for the fulfillment of the overall objective.
Built using the powerful Unreal Engine 3.0, Hour of Victory combines authentic details from historic World War II battles and adds frenetic and cinematic gameplay. Players will also be able to jump in and out of vehicles on the battlefield whenever they wish.
About Midway
Midway Games Inc. (NYSE:MWY), headquartered in Chicago, Illinois, with offices throughout the world, is a leading developer and publisher of interactive entertainment software for major videogame systems and personal computers. More information about Midway and its products can be found at www.midway.com.
HOUR OF VICTORY is a trademark of Midway Home Entertainment Inc. "Xbox" and "XBOX 360" are registered trademarks of Microsoft Corporation in the United States and/or other countries. Unreal(R) is a registered trademark of Epic Games, Inc. All other trademarks are the property of their respective companies.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 concerning future business conditions and the outlook for Midway Games Inc. (the "Company") based on currently available information that involves risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, including, without limitation, the financial strength of the interactive entertainment industry, dependence on new product introductions and the ability to maintain the scheduling of such introductions, the current console platform transition and other technological changes, dependence on major platform manufacturers and other risks more fully described under "Item 1. Business - Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and in any more recent filings made by the Company with the Securities and Exchange Commission. Each forward-looking statement, including, without limitation, financial guidance, speaks only as of the date on which it is made, and Midway undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances, except as required by law.
Source: Midway Games Inc.
----------------------------------------------
Midway Media Relations
Johner Riehl
858-790-3749
jriehl@midway.com
or
Midway Media Relations
Reid Druck
858-790-3768
rdruck@midway.com
or
Midway - Investor Relations
Geoffrey Mogilner
773-961-2222
gmogilner@midway.com
MSPD 2.30 China's Datang Mobile Deploys Mindspeed(R) OptiPHY(TM) Interface in 3G Base Station
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Mindspeed Technologies, Inc. (NASDAQ:MSPD), a leading supplier of semiconductor solutions for network infrastructure applications, today announced that Datang Mobile is shipping Mindspeed's OptiPHY ATM packet-over-SONET (POS) PHY in its 3G wireless base stations.
Datang Mobile is a leading communications equipment company in China dedicated to developing products for 3G networks based on time division - synchronous code division multiple access (TD-SCDMA). TD-SCDMA is one of the 3G mobile communications standards in China and construction of large-scale trial networks is currently underway in 10 cities, including Beijing, in preparation for the 2008 Olympic Games.
Datang Mobile's base station product range includes Micro Node B and Macro Node B based on ATM which allows a smooth migration to IP. Datang Mobile solutions can be deployed in dense urban areas as well as suburban and rural areas. Node B advantages include high integration, low power consumption and large capacity for network buildout.
"Mindspeed is committed to providing industry leading solutions for 3G wireless backhaul applications with a full range of physical layer and traffic management products that support both ATM and IP," said Taqi Mohiuddin, executive director of marketing for Mindspeed.
The OptiPHY CX2970x family implements one, two or four-channel ATM and POS/SDH processing. Each device has clock and data recovery allowing superior jitter performance. Mindspeed's Telecom Application Package (TAP) software is available for the CX2970x family of devices, and is characterized by a well-defined application programming interface (API) that allows easy integration with higher-level application software and shortens the development cycle increasing time-to-market.
About Mindspeed Technologies(R)
Mindspeed Technologies, Inc. designs, develops and sells semiconductor networking solutions for communications applications in enterprise, access, metropolitan and wide area networks.
The company's three key product families include high-performance analog transmission and switching solutions, multiservice access products designed to support voice and data services across wireline and wireless networks, and WAN communications solutions including T/E carrier physical-layer and link-layer devices as well as ATM/MPLS network processors.
Mindspeed's products are used in a wide variety of network infrastructure equipment including voice and media gateways, high-speed routers, switches, access multiplexers, cross-connect systems, add-drop multiplexers and digital loop carrier equipment.
To learn more, visit us at www.mindspeed.com.
About Datang Mobile
Datang Mobile, a leading Chinese telecom equipment manufacturer, is one of the core members of Datang Telecom Technology and Industry Group. The company headquarters in Beijing, with one subsidiary in Shanghai and one branch in Xi'an.
Datang Mobile is dedicated to the research and development of TD-SCDMA, a home grown international 3G standard. With the operation principle of "joint development, virtual manufacture and entrusted operation," and on the basis of its self-own core intellectual property right and the whole series products including infrastructure and terminal, Datang Mobile is committed to providing the total solution for the customers in the area of public and private communication networks.
Safe Harbor Statement
This press release contains statements relating to Mindspeed, and our future results, including certain projections and business trends, that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results, and actual events that occur, may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: market demand for our new and existing products and our ability to increase our revenues; our ability to maintain operating expenses within anticipated levels; our ability to reduce our cash consumption; availability and terms of capital needed for our business; constraints in the supply of wafers and other product components from our third-party manufacturers; our ability to successfully and cost effectively establish and manage operations in foreign jurisdictions; the ability to attract and retain qualified personnel; successful development and introduction of new products; our ability to obtain design wins and develop revenues from them; pricing pressures and other competitive factors; order and shipment uncertainty; changes in our customers' inventory levels and inventory management practices; fluctuations in manufacturing yields; product defects; and intellectual property infringement claims by others and the ability to protect our intellectual property, as well as other risks and uncertainties, including those detailed from time to time in our Securities and Exchange Commission filings.
Source: Mindspeed Technologies, Inc.
----------------------------------------------
Mindspeed Technologies
Inc.
Editorial Contact:
Tom Stites
949-579-3650
or
Investor Relations Contact:
Simon Biddiscombe
949-579-6283
CHIP 7.98 VeriChip Corporation Launches New Customer Support Initiative for Infant Protection
By Your Side Program Sets New Standard in Support
Jun 25, 2007 8:30:00 AM
Copyright Business Wire 2007
DELRAY BEACH, Fla.--(BUSINESS WIRE)--
VeriChip Corporation (Nasdaq:CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today its wholly owned subsidiary, Xmark Corporation, launched the By Your Side(TM) program for its infant protection products at the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) Convention in Orlando, FL.
The By Your Side program provides Xmark's infant protection customers with an unmatched level of support to ensure success with their Halo or Hugs infant protection system. It is Xmark's commitment that every customer will be successful with infant protection.
The program has five main components: Implementation Support, Clinical Education, Parent Education, Public Relations and Continuing Clinical Support. Created with substantial input from current customers, industry experts and Xmark's clinical education staff, the program is designed to provide customers with close and continuing support throughout the product life cycle, from initial purchase to implementation to ongoing use.
Speaking from the AWHONN Convention, Daniel A. Gunther, President and CEO of Xmark, said, "Xmark's dominance of the infant protection market is the result of listening closely to our customers and giving them products that work in their environment. The By Your Side program is the next step in our efforts to truly partner with our customers and provide the best possible infant protection. It's a commitment for the long term that none of our competitors have made."
The AWHONN Convention is the nation's largest gathering of nurses, nurse practitioners and nurse executives in the field of maternal/child care. By launching the By Your Side program at the show, Xmark is reaching directly more than 2000 decision makers who drive the purchase of infant protection systems.
Xmark's Halo system and Hugs system are part of its industry-leading portfolio of infant protection products. One out of every three infant protection systems in the United States is an Xmark product.
For more information on Xmark's products, please contact 1-866-55-XMARK or email sales@xmark.com. Additional information can be found online at www.xmark.com.
About Xmark
Based in Ottawa, Ontario, Xmark is a wholly owned subsidiary of VeriChip Corporation. For over 25 years, Xmark Corporation has provided Radio Frequency Identification (RFID) solutions to identify, locate, and protect people and assets in healthcare environments. Its market-leading infant protection, wander prevention, personal duress, and asset tracking applications are trusted by over 5,000 healthcare institutions worldwide to keep individuals safe.
Xmark products are installed and serviced through an international network of authorized dealers, backed by a dedicated technical services department at Xmark. All aspects of Xmark's business are certified to the ISO 9001 quality standard.
About VeriChip
VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.
VeriChip Corporation is majority-owned by Applied Digital Solutions Inc. (NASDAQ:ADSX), which also owns a majority position in Digital Angel Corporation (AMEX:DOC). For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com.
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
Source: VeriChip Corporation
----------------------------------------------
VeriChip Corporation
Delray Beach
Allison Tomek
561-805-8008
atomek@adsx.com
or
CEOcast
Dan Schustack
212-732-4300
Cyber Criminals Rely On Mind Games To Scam Internet Users
McAfee Study Offers Insight into Psychological Tactics Used in Online Scams
Jun 25, 2007 8:25:00 AM
SANTA CLARA, Calif., June 25 /PRNewswire-FirstCall/ -- McAfee, Inc. (NYSE: MFE) today announced the results of a groundbreaking study that details the psychological games and other tactics cyber criminals use in social engineering scams propagated through junk email. In the study titled "Mind Games," the primary author, Dr. James Blascovich, Professor of Psychology at the University of California, Santa Barbara, offers analyses of multiple common scam emails and provides surprising insights into how cyber criminals use fear, greed and lust to methodically steal personal and proprietary financial information.
The same psychological practices used by cyber criminals were also investigated in a European report, commissioned by McAfee(R) in association with leading forensic psychologist, Professor Clive Hollin, based at University of Leicester in the United Kingdom.
"Scam spam works best by providing recipients with a sense of familiarity and legitimacy, either by creating the illusion that the email is from a friend or colleague, or providing plausible warnings from a respected institution," Dr. Blascovich noted. "Once the victim opens the email, criminals use two basic motivational processes, approach and avoidance, or a combination of the two, to persuade victims to click on dangerous links, provide personal information, or download risky files. By scamming $20 from just half of one percent of the U.S. population, cyber criminals can earn $15 million each day and nearly $5.5 billion in a year, a powerful attraction for skillful scam artists."
An important key to the crooks' success is familiarity. One example is phishing scams which fraudulently acquire sensitive information, such as usernames, passwords, and financial data, by masquerading as a familiar or nationally recognized bank, credit card company or even an online auction site. Recently, McAfee Avert(R) Labs found that the number of phishing Web sites increased by 784 percent in the first half of 2007.
Popular sites are also increasingly victimized. In December of 2006, cyber criminals targeted MySpace and used a worm to convert legitimate links to those that lured consumers to a phishing site designed specifically to obtain personal information.
"Along with the alarming increase in phishing emails, we are also seeing more sophisticated messages that can fool all but the most highly trained surfer," said David Marcus, security research and communications manager, McAfee Avert Labs. "While earlier phishing emails often included typos, awkward language and minor graphical mistakes, newer scams appear to be more legitimate, with slicker graphics and copy that closely mirrors the language used by respected institutions."
In addition to tactics that build on familiarity to create the illusion of legitimacy, phishing scams also target consumers with fear tactics, such as through subject lines like "Urgent Security Notification" and "Your billing account records are out of date." Other lures, such as "Must Complete and Submit" or "You Are Missing Out," are less blatant but similarly trick users
into thinking that without a specific action on their part, they're going to lose out.
Dr. Blascovich also reports on a category of scam emails that target consumers who are promotion focused (want to "get ahead") and/or capitalize on consumers' greed. These messages have such subject lines as "You Won" to entice consumers into thinking they may have won a lottery or sweepstakes, "90% discounts" to trick consumers into thinking they are getting great promotional pricing, or "You Are Approved" to target consumers who need a loan or have money woes.
Yet another popular lure involves messages that play on feelings of love and loss. A subject like "Why spend another week lonely?" works by preying on the sensitivities of those feeling vulnerable. And finally, there's the voice- of-authority approach: "Attention! Several Credit Card databases have been LOST" and others like it are designed to make consumers feel a sense of urgency and obligation.
Additional in-depth information on top phishing scams and security threats is available at the McAfee Threat Center at http://www.mcafee.com/us/threat_center/default.asp.
The "Mind Games," report is available online at http://www.mcafee.com/us/threat_center/white_paper.html.
Notes to Editors:
Research Methodology: McAfee's Avert Labs team identified real examples of common phishing scams to be analyzed by Dr. James Blascovich for the Mind Games study. The samples gathered by McAfee were categorized to reflect the tone of the message (e.g., "Voice of Authority"), or the content of the message (e.g. "Competition Winners"), or the type of emotional manipulation (e.g. "Playing on Embarrassment). This categorization of material from real sites provided the material for analysis by Dr. Blascovich.
About McAfee, Inc.
McAfee, Inc. is the leading dedicated security technology company. Headquartered in Santa Clara, California, McAfee delivers proactive and proven solutions and services that secure systems and networks around the world. With its unmatched security expertise and commitment to innovation, McAfee empowers home users, businesses, the public sector, and service providers with the ability to block attacks, prevent disruptions, and continuously track and improve their security. http://www.mcafee.com.
NOTE: McAfee and Avert are trademarks or registered trademarks of McAfee, Inc. and/or its affiliates in the U.S. and/or other countries. McAfee Red in connection with security is distinctive of McAfee brand products. All other registered and unregistered trademarks herein are the sole property of their respective owners. (C) 2007 McAfee, Inc. All rights reserved.
SOURCE McAfee, Inc.
----------------------------------------------
Francie Coulter of McAfee
Inc.
+1-408-992-8407
francie_coulter@mcafee.com
or Eric Goldman of GlobalFluency
+1-646-652-5203
egoldman@globalfluency.com
for McAfee
Inc.
INTV 8.01 Intervoice Resolves Pending Proxy Contest
Former Chairman and CEO David W. Brandenburg and Co-Founder Daniel D. Hammond to Rejoin the Board
Jun 25, 2007 8:01:00 AM
Copyright Business Wire 2007
DALLAS--(BUSINESS WIRE)--
Today Intervoice, Inc. (NASDAQ: INTV) announced an agreement appointing David W. Brandenburg, Daniel D. Hammond and Timothy W. Harris to the Intervoice Board, ending the proxy contest that was to occur at the Company's 2007 Annual Meeting of Shareholders. Mr. Brandenburg, Mr. Hammond and Mr. Harris have each been appointed to the Intervoice Board effective June 22, 2007, and they will also be added to the Company's revised slate of director nominees for one-year terms at the Annual Meeting. Concurrently with his appointment to the Company's Board, Mr. Brandenburg was also elected Chairman and Mr. Hammond was elected Vice-Chairman. The slate of director nominees to be presented by the Company for election at the 2007 Annual Meeting of Shareholders will now consist of the following seven persons: David W. Brandenburg, Daniel D. Hammond, Timothy W. Harris, Gerald F. Montry, George C. Platt, Donald B. Reed and Robert E. Ritchey. Gerald F. Montry, George C. Platt, Donald B. Reed and Robert E. Ritchey are all current members of the Intervoice Board.
"Intervoice's Board is very pleased to have reached this agreement and to be able to welcome back to the Intervoice Board Mr. Brandenburg and Mr. Hammond, both of whom have a deep understanding of Intervoice's business and industry and are very familiar with our customers, partners and products," said Bob Ritchey, President and CEO. "We are also delighted to welcome Mr. Harris as a new member and one who brings to Intervoice's Board a strong financial and operating background in the technology sector. We all look forward to working with Mr. Brandenburg, Mr. Hammond and Mr. Harris to create an exciting future for Intervoice's shareholders, employees, customers and partners worldwide."
To accommodate the resolution of the pending proxy contest, Saj-nicole Joni, Joseph Pietropaolo and Jack Reily agreed at the request of Intervoice to resign from the Board to enable Mr. Brandenburg, Mr. Hammond and Mr. Harris to join the Board promptly after the directors' resignations. "I know that I speak for the entire Board and the Intervoice management team in expressing to each of the departing directors our heartfelt appreciation and gratitude for the dedicated service, commitment and leadership that they each provided to the Company during their tenure on the Board," said Mr. Ritchey. "Intervoice is a better and stronger company, from both an operational and governance perspective, because of the contributions that each made as a member of the Board."
"Dan Hammond and I are excited to re-join the Intervoice Board, along with Tim Harris, at a pivotal point in the company's history," said Mr. Brandenburg. "I've always believed that Intervoice is a great Company with tremendous leadership worldwide in the voice-automation market. It has been blessed with great technology, great employees, a "blue-chip" roster of customers and a great and very talented management team. We look forward to supporting management in its efforts to have the Company enter an exciting new era of market leadership. We believe that working together in a constructive fashion with the other members of the Board and the Company's management team, we can make a strong contribution to the future success of Intervoice. Our recent conversations with management and representatives of the Board have been very encouraging and have only validated our belief about the quality, character and potential of the Intervoice organization and the commitment we all share to enhancing shareholder value. With all parties working together constructively to look at the issues and to design new solutions for the future, there is no reason that Intervoice cannot make strong progress in a number of key areas. I'm confident that today's announcement is the right decision for all concerned parties."
Mr. Brandenburg is a former Chairman, Vice Chairman, Chief Executive Officer and President of Intervoice. He first joined Intervoice as Chief Operating Officer in July 1990 after having served as a director since 1989 and served as President from 1991 to 1994 and Vice Chairman from 1994 to 1995. Mr. Brandenburg re-joined Intervoice as Chief Executive Officer in 2000 and also served as Chairman of the Board until his retirement in November 2004. He left the Company's Board of Directors in December 2004 following his retirement from the Company. In addition to his long association with Intervoice, from November 1997 to May 1998, Mr. Brandenburg served as President and Chief Executive Officer of AnswerSoft, Inc., a global provider of call center software automation solutions that has since been acquired by a predecessor to Aspect Software, Inc.
Mr. Hammond is a founder of Intervoice and served as its Chief Executive Officer from June 1986 to June 2000. He served on Intervoice's Board of Directors from January 1984 until December 2000 and as Chairman of its Board from December 1990 until December 2000. He then served as an advisor to Intervoice from January 2001 until February 2004. He is the named inventor of five U.S. patents issued to Intervoice and one pending U.S. patent. Mr. Hammond is currently the President of Hammond Development International, Inc.
Mr. Harris currently serves as the President and Chief Executive Officer of Questia Media, Inc., a privately-held provider of online digital libraries. He served on the Board of Directors of Questia Media from December 2002 to the present. Prior to his role as Chief Executive Officer, he held various executive positions with the company from 1999 to 2004 including Vice President and Chief Operating Officer and Vice President and Chief Financial Officer. Prior to joining Questia Media, he worked for Compaq Computer Corporation for 15 years beginning in 1983 in various positions culminating as Vice President and General Manager of their Commercial Desktop Division. Prior to that position, he served in various executive and financial positions including having financial responsibility for worldwide manufacturing operations.
Intervoice also announced today that its 2007 Annual Meeting of Shareholders will be held on Monday, July 23, 2007 at 3:00 pm CDT at the Intercontinental Hotel in Dallas, Texas.
IMPORTANT INFORMATION
Certain matters discussed in this press release are covered by the Board Representation and Governance Agreement ("Agreement") entered into between Intervoice and David W. Brandenburg pursuant to which the parties ended the proxy contest that was to occur at the Company's 2007 Annual Meeting of Shareholders. This press release does not purport to be a complete description of the Agreement and is qualified in its entirety by reference to the full text of the Agreement which Intervoice intends to file with the Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K. The complete text of the Agreement is being publicly filed to provide investors with information regarding its terms. It is not intended to provide any other factual information about Intervoice.
Intervoice and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Intervoice shareholders. Certain information regarding the participants and their interests in the solicitation will be set forth in the definitive proxy statement for Intervoice's 2007 annual meeting of shareholders, which will be available free of charge from the SEC and Intervoice at their websites as indicated below.
Intervoice intends to file a definitive proxy statement with the Securities and Exchange Commission containing information with respect to the revised slate of nominees being proposed for election at the 2007 annual meeting. Shareholders are advised to read the proxy statement and other documents related to the solicitation of proxies from shareholders of Intervoice for use at the 2007 annual meeting when they become available because they will contain important information. When completed, a definitive proxy statement and a form of proxy will be mailed to Intervoice's shareholders and will be available, along with other relevant documents, at no charge, at the Securities and Exchange Commission's website at http://www.sec.gov or by contacting Georgeson Inc. by telephone at (888) 605-7534.
About Intervoice, Inc.
Intervoice is a world leader in unified communications, providing scalable, switch-independent software and professional services that power standards-based voice portals, multi-channel IP contact centers, and next-generation mobile-enhanced services. Since 1983, Intervoice solutions have been used by many of the world's leading banks, communications companies, healthcare institutions, utilities and government entities. With more than 5,000 customers in 75 countries, Intervoice helps enterprises and network operators stay competitive by offering their customers best-in-class services. Intervoice Voice Portal, IP contact center software, IMS-enabled messaging products, Media Exchange platform and custom-built and packaged applications are available on-premise and, selectively, as managed or hosted services by Intervoice. For more information, visit www.intervoice.com.
Forward-Looking Statements
Intervoice has included in this press release certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's current beliefs. All statements other than statements of historical fact in this press release are forward-looking statements. Readers are cautioned to read the risks and uncertainties, described in the Company's filings with the Securities and Exchange Commission, including without limitation, the risks and uncertainties set forth under the caption entitled "Cautionary Disclosures to Qualify Forward Looking Statements" in the Company's Annual Report filed on Form 10-K and Quarterly Reports filed on Form 10-Q. Intervoice cautions current and potential investors that such risks and uncertainties could result in material differences from the forward-looking statements in this press release.
Intervoice(R) is a registered trademark and HomeZone(TM) is a trademark of Intervoice Limited Partnership. Names and marks for products provided by Intervoice partners and/or suppliers are used herein for identification purposes and may be trademarks of their respective companies.
Source: Intervoice, Inc.
----------------------------------------------
Intervoice
Inc.
Corbin Baumel
972-454-8737
corbin.baumel@intervoice.com
CNXT 1.47 Conexant Names New President and Chief Executive Officer
Daniel Artusi Succeeds Dwight Decker, Who Will Continue as Non-Executive Chairman
Jun 25, 2007 8:01:00 AM
Copyright Business Wire 2007
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Conexant Systems, Inc. (Nasdaq:CNXT) today announced that Daniel Artusi will join the company as president and chief executive officer. His first day with Conexant will be Monday, July 9, 2007. He will also become a member of the company's board of directors.
Artusi, 52, succeeds Dwight W. Decker, 57, who in March of this year announced plans to retire. At that time, Conexant's board initiated the search for Decker's successor. Decker will continue to serve the company as non-executive chairman of the board.
For the past two years, Artusi has been chairman and chief executive officer of ColdWatt, Inc., a privately held company that provides high-efficiency power supplies to the communications and computer industries. Before that, he spent four years with Silicon Laboratories, Inc., a designer and manufacturer of mixed-signal integrated circuits, most recently as president and chief executive officer. Prior to joining Silicon Labs, Artusi spent 24 years with Motorola's Semiconductor Products Sector in a variety of positions that included corporate vice president and general manager, Networking and Computing Systems Group; vice president and general manager, Wireless Infrastructure Systems Division; and general manager of the RF Semiconductor Division. Artusi studied electrical engineering at the Instituto Tecnologico de Buenos Aires in Argentina.
"I'm excited about joining Conexant as president and chief executive officer and eager to begin my new assignment," Artusi said. "I'd like to thank the board of directors for giving me the opportunity to lead the company by applying the skills and experience I've acquired over three decades in the semiconductor industry. Conexant has a rich and storied history, and the company continues to address some of our industry's most exciting, highest-growth opportunities with an outstanding portfolio of communications products and technologies. We face near-term challenges, but I am confident that we possess the talent and market positions required to build significant shareholder value."
Decker joined Rockwell International in 1989 and served as Conexant's chairman and chief executive officer from the time of the company's spin-off from Rockwell in January 1999 through February 2004, when the company's merger with GlobespanVirata was completed. At that point he announced his retirement and became non-executive chairman of the board of the combined company. In November 2004, he agreed to come out of retirement and resume his duties as chief executive officer.
"I couldn't be more pleased with the board's selection of Dan as my successor," Decker said. "He's an experienced chief executive officer with an impressive record of accomplishment. Throughout his career with ColdWatt, Silicon Labs, and Motorola, he has consistently demonstrated the leadership, focus, and technical expertise required to deliver outstanding results on a regular basis. Dan is the right leader for Conexant at this time. I look forward to resuming my retirement, and to serving as non-executive chairman of Conexant's board of directors."
Jerre L. Stead, chairman of the board's management development and compensation committee, served as chairman of the chief executive officer search committee.
"We considered a full slate of qualified candidates and are delighted that Dan has chosen to become Conexant's president and chief executive officer at a critical juncture for the company," Stead said. "The board and I are convinced that Dan's outstanding business and technical capabilities, motivational leadership style, and ability to articulate clear, concise strategies are a perfect match for Conexant's current needs. Once again, I'd like to thank Dwight for his leadership, contributions, and dedication over the years. Dwight and the entire Conexant team accomplished a great deal, and much remains to be done. I am confident that Dan will lead the company to a new level of competitiveness, performance, and accomplishment."
About Conexant
Conexant's innovative semiconductor solutions are driving broadband communications and digital home networks worldwide. The company has leveraged its expertise and leadership position in modem technologies to enable more Internet connections than all of its competitors combined, and continues to develop highly integrated silicon solutions for broadband data and media processing networks.
Key products include client-side xDSL and cable modem solutions, home network processors, broadcast video encoders and decoders, digital set-top box components and systems solutions, and dial-up modems. Conexant's suite of networking components includes a leadership portfolio of IEEE 802.11-compliant WLAN chipsets, software and reference designs, as well as solutions for applications based on HomePlug(R) and HomePNA(TM). The company also offers a complete line of asymmetric and symmetric DSL central office solutions, which are used by service providers worldwide to deliver broadband data, voice, and video over copper telephone lines.
Conexant is a fabless semiconductor company that recorded revenues of $970.8 million in fiscal year 2006. The company has approximately 3,200 employees worldwide, and is headquartered in Newport Beach, Calif. To learn more, please visit www.conexant.com.
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Conexant or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.
These risks and uncertainties include, but are not limited to: the risk that capital needed for our business and to repay our indebtedness will not be available when needed; the risk that the value of our common stock may be adversely affected by market volatility; general economic and political conditions and conditions in the markets we address; the substantial losses we have incurred; the cyclical nature of the semiconductor industry and the markets addressed by our products and our customers' products; continuing volatility in the technology sector and the semiconductor industry; demand for and market acceptance of our new and existing products; our successful development of new products; the timing of our new product introductions and our product quality; our ability to anticipate trends and develop products for which there will be market demand; the availability of manufacturing capacity; pricing pressures and other competitive factors; changes in our product mix; product obsolescence; the ability of our customers to manage inventory; our ability to develop and implement new technologies and to obtain protection for the related intellectual property; the uncertainties of litigation, including claims of infringement of third-party intellectual property rights or demands that we license third-party technology, and the demands it may place on the time and attention of our management and the expense it may place on our company; and possible disruptions in commerce related to terrorist activity or armed conflict, as well as other risks and uncertainties, including those detailed from time to time in our Securities and Exchange Commission filings.
The forward-looking statements are made only as of the date hereof. We undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Conexant is a registered trademark of Conexant Systems, Inc. Other brands and names contained in this release are the property of their respective owners.
Source: Conexant Systems, Inc.
----------------------------------------------
Conexant Systems
Inc.
Editorial Contact:
Gwen Carlson
949-483-7363
Investor Relations Contact:
Bruce Thomas
949-483-2698
VION 1.12 Vion Pharmaceuticals to Hold Annual Meeting of Stockholders
Jun 25, 2007 8:00:00 AM
NEW HAVEN, Conn., June 25 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company's Annual Meeting of Stockholders will be held Tuesday, June 26, 2007 at The Stamford Marriott Hotel, 243 Tresser Boulevard, Stamford, Connecticut. The meeting will begin at 10:00 a.m. Eastern Time.
Vion's Chief Executive Officer, Alan Kessman, will make a presentation on the Company at the meeting. Slides from the presentation will be available on the Company's website, www.vionpharm.com, after 10:00 a.m. on June 26th.
Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.
This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
COMPANY CONTACT: Vion Pharmaceuticals, Inc.
Alan Kessman, Chief Executive Officer
Howard B. Johnson, President & CFO
(203) 498-4210 phone
SOURCE Vion Pharmaceuticals, Inc.
----------------------------------------------
Alan Kessman
Chief Executive Officer
or Howard B. Johnson
President & CFO
both of Vion Pharmaceuticals
Inc.
+1-203-498-4210
ONT 3.04 On2 Technologies Joins Russell 3000 Index
Jun 25, 2007 8:00:00 AM
TARRYTOWN, N.Y., June 25 /PRNewswire-FirstCall/ -- On2 Technologies, Inc., (Amex: ONT), a leader in video-compression software and solutions, announced today that it joined the Russell 3000(TM) Index on June 22, when Russell Investment Group reconstituted its family of U.S. indexes.
Membership in the broad-market Russell 3000, which remains in place for one year, means automatic inclusion in additional Russell Indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
"We are pleased to join the Russell Indexes, which reflects in part our stock appreciation resulting from initiatives over the past year," said Bill Joll, president and CEO of On2. "Our inclusion in the Russell 3000 should increase On2's visibility with investors and institutions that rely on the Russell indexes as part of their investment strategy."
Annual reconstitution of the Russell indexes captures the 3,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Investment managers who oversee these funds purchase shares of member stocks according to that company's weighting in the particular index. An industry-leading $4 trillion in assets currently are benchmarked to them.
About Russell Investment Group
Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.
About On2 Technologies, Inc.
On2 Technologies (Amex: ONT) is a leading technology firm at the forefront of digital video compression. The company revolutionized digital media delivery with the creation of its advanced full-motion, full-screen On2 Video compression and streaming technologies. On2 Video codecs are widely used in the Internet, video-on-demand, VoIP, and mobile media markets. On2's software is used by such leading global companies as Adobe/Macromedia, AOL, Skype, XM Satellite Radio, Sony, CTTNet, VitalStream, and Tencent. Located in Tarrytown, N.Y., the company has R&D offices in Clifton Park, N.Y., and Cambridge, UK. To contact On2, write to sales@on2.com or visit http://www.on2.com.
Trademarks mentioned in this release are property of their respective owners.
SOURCE On2 Technologies, Inc.
----------------------------------------------
Sam Vasisht of On2 Technologies
+1-518-724-3872
svasisht@on2.com
DESC 1.27 Distributed Energy Systems Books African Hydrogen Order; Commissions Hydrogen Vehicle Fueling System in Florida
Jun 25, 2007 8:00:00 AM
WALLINGFORD, Conn., June 25 /PRNewswire-FirstCall/ -- Distributed Energy Systems Corp. (Nasdaq: DESC) today announced an order for a hydrogen- generation and storage system for a new electric power plant in Africa. The company, which creates and delivers products and solutions to the emerging decentralized energy marketplace, also said it completed installation and commissioning of an advanced hydrogen vehicle fueling station in Florida, under a contract with a major global energy corporation and a large international chemical company. Terms of the two projects were not disclosed.
The North African sale, to a major international generator manufacturer, is for a complete hydrogen supply and storage system to "cool" the electricity generators that will be installed at a new power plant now under construction. The installation will include two HOGEN(R) H-Series hydrogen generating units and gas compression and storage systems, to be delivered in the fourth quarter of 2007. The company said the order reflects growing demand for its products in the global generator cooling market.
The Florida project involved successfully installing and commissioning an on-site hydrogen vehicle fueling system at a service station in Orlando. The station showcases the company's proton exchange membrane electrolysis (PEM) technology, which uses electrical energy to convert water into hydrogen fuel that can be safely stored at the station, and dispensed into clean and efficient hydrogen-fueled automobiles. The Orlando station is one of 14 such hydrogen fueling locations Distributed Energy Systems has helped develop since 2002.
About Distributed Energy Systems Corp.
Distributed Energy Systems Corp. (Nasdaq: DESC) creates and delivers products and solutions to the emerging decentralized energy marketplace, giving users greater control over their energy cost, quality and reliability. The company delivers a combination of practical, ready-today energy solutions and solid business platforms for capitalizing on the changing energy landscape. For more information visit http://www.distributed-energy.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements contained herein concerning Distributed Energy Systems' goals, future revenue and profitability, financial sustainability, and anticipated growth and other statements that are not statements of historical fact may be deemed to be forward-looking information. Without limiting the foregoing, words such as "anticipates", "believes", "could", "expect", "intend", "may", "might", "should", "will", and "would" and other forms of these words or similar words are intended to identify forward-looking information. Distributed Energy Systems' actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. Distributed Energy Systems disclaims any obligation to update these forward-looking statements. Factors that could cause results to differ materially from those contained in Distributed Energy Systems' forward-looking statements include, but are not limited to, our failure to perform contracts for customers profitably, or complete development of our products, the failure of our products to achieve commercial acceptance, our inability to expand our production facilities, manufacture our products at commercially acceptable costs or establish distribution relationships, the impact of competitive products, and other factors detailed in Distributed Energy Systems' Form 10-Q for the quarter ended March 31, 2007, and other filings Distributed Energy Systems may make from time to time with the SEC.
SOURCE Distributed Energy Systems
----------------------------------------------
Peter J. Tallian
Chief Financial Officer
Distributed Energy Systems
+1-203-678-2148
TTPA 4.25 Concuity Announces the Availability of EOB PRO for Healthcare Providers
Concuity's EOB PRO Integrates EOB Conversion Capabilities into its Contract and Denials Management Software, ClearContracts(TM)
Jun 25, 2007 8:00:00 AM
VERNON HILLS, Ill., and DUBLIN, Ireland, June 25 /PRNewswire-FirstCall/ -- Concuity, a healthcare division of Trintech (Nasdaq: TTPA), today announced the availability of EOB PRO for ClearContracts, its web-based, revenue cycle management system. ClearContracts helps healthcare providers identify and correct underpayments due to payer non-compliance in the contract revenue cycle. EOB PRO converts paper-based Explanation of Benefits (EOBs) into HIPAA standard 835s, eliminating the intensive, manual process of posting paper EOB payments to a healthcare billing system.
EOB PRO allows providers to consolidate various paper and/or electronic remittances into a single stream of data that eliminates time-consuming and error-prone manual data entry; enhances the ability to recover revenue; provides image and data archive capabilities; and increases control and visibility into healthcare transaction processes. With EOB PRO, providers can focus on other core business issues, such as identifying denied, delayed, and inaccurate reimbursements identified in the ClearContracts solution.
"Today, EOB PRO is performing daily paper EOB conversion for a large healthcare system in the northeastern United States. They're converting thousands of paper-based transactions per month for regional and national payers," said David Rodriguez, Director of Product Marketing. "Since implementing EOB PRO, the healthcare system has not needed to hire additional staff to post payments, reduced the need for mandatory overtime for current staff, and eliminated the need for additional office space to house both staff and documents."
By utilizing EOB PRO in conjunction with ClearContracts, clients maximize their return on investment. All transactions are integrated, and 100% transparency is provided to all remittances. For clients contending with underpayments and denials, this provides both savings in time and recovered dollars. EOB PRO captures all patient and payment data from EOBs, as well as normalizing EOB reason codes, which is essential for denials management.
"Our goal is to help healthcare providers solve operational issues while improving their margin and cash flow," said Ed Gallo, EVP Healthcare Business Group, Trintech. "With EOB PRO and ClearContracts providers can automate claims billing processes, increase clean claim submissions, and improve resource allocation; thereby, generating a higher level of financial performance that will drive the quality of care and efficiency in our healthcare system."
About Concuity
Concuity offers industry-leading solutions to increase hospital revenue by identifying and correcting payer non-compliance issues in the contract revenue cycle. Founded in 2000 by a group of healthcare industry visionaries and now a valued Division of Trintech, Concuity improves its customers' bottom lines by delivering technology and service solutions to create and negotiate better contracts, ensure accurate implementation and compliance, and collect what's owed. Clients include University of Utah Hospitals and Clinics, Salt Lake City, UT, Riverside Medical Center, Kankakee, IL and Providence Health System, Seattle, WA. Concuity is headquartered in Vernon Hills, Ill. For more information, call 847-465-6003 or visit http://www.concuity.com.
About Trintech Group
Trintech Group Plc (Nasdaq: TTPA) is a leading global provider of financial software and services specializing in reconciliation workflow, revenue enhancement, transaction risk management, and compliance for commercial, financial, and healthcare markets. For over 20 years, Trintech has been providing comprehensive, industry-leading solutions to financial departments seeking greater insight into critical transaction processes. Trintech delivers a configurable, highly scalable platform that incorporates a company's unique business processes, enabling managers to obtain greater visibility and more efficiently manage business risk throughout the transaction lifecycle. Trintech's transaction process management solutions include: ReconNET for high volume transaction reconciliation; AssureNET GL for general ledger reconciliation and certification; On-Demand solutions for ASP ReconNET and AssureNET services and the Dataflow Transaction Network for data collection and delivery; and ClearContracts, an ASP service which enables health care providers to optimize contract profitability by reconciling payments received from their patients' insurers to amounts they should have received from claims under the terms of their respective contracts. Over 450 leading companies across a variety of industries rely on Trintech products and services. Clients include: North Fork Bank, 7-Eleven, Kroger, Regal Entertainment, Accor, UPMC, Farmer's Insurance Group, YUM! Brands Restaurants, Rohm and Haas, Verizon Wireless, and Ameren.
Trintech's principal business office is in Dallas, Texas, with international offices in Ireland, the United Kingdom and the Netherlands. Trintech can be reached at 15851 Dallas Parkway, Suite 900, Addison, TX 75001 (Tel 1.972.701.9802). Trintech's corporate office can be contacted at Trintech Technologies, Block C, Central Park, Leopardstown, Dublin 18, Ireland (Tel 353.1.293.9840). For more information, please visit http://www.trintech.com.
Trintech Press Contact:
Dallas: Donna Martinez, Marketing Communications Manager, Trintech
Tel. +1 972 739 1611. email:donna.martinez@trintech.com
SOURCE Trintech Group Plc
----------------------------------------------
Donna Martinez
Marketing Communications Manager of Trintech
+1-972-739-1611
donna.martinez@trintech.com
AMY 8.20 AmREIT Announces Share Repurchase Program
Jun 25, 2007 8:00:00 AM
HOUSTON, June 25 /PRNewswire-FirstCall/ -- AmREIT (Amex: AMY), a Houston- based real estate investment trust, announced today that its Board of Trustees authorized up to $5 million for the purchase of outstanding Class A Common Shares of Beneficial Interest. Share repurchases may be made in the open market or in privately negotiated transactions at the discretion of the Company's management, and as market conditions warrant. The share repurchase program will be funded with available cash or other financing proceeds and may be discontinued at any time.
"Given current market prices, we believe executing a share repurchase program allows us to pursue an attractive investment opportunity," said Kerr Taylor, AmREIT's chief executive officer. "As we have demonstrated in the past with previous share repurchases and other capital structure initiatives, we search for investment opportunities which best benefit the long-term interests of the Company and our shareholders. We will balance our share repurchase program with other investment alternatives."
About AmREIT
AmREIT (Amex: AMY) is a growing real estate company that has delivered results to its investors for 22 years. Our mission is to build a real estate business with complementary operations that reduce our overall sensitivity to changing market cycles -- a company with strong earnings potential from multiple sources. This mission has led AmREIT into three distinct businesses. First, as a real estate development and operating company, it constructs, develops, acquires, disposes of, brokers, leases and manages properties for shareholders as well as for its asset advisory group and third parties. Second, AmREIT has an asset advisory group which raises private capital for and generates fees from merchant development partnership funds. Third, AmREIT owns a portfolio of "Irreplaceable Corners(TM)" -- premier retail properties in high-traffic, highly populated areas -- which are held for long-term value and provide a steady stream of rental income. As of March 31, 2007, AmREIT has over 1.2 million square feet of retail centers in various stages of re- development, development or in the pipeline for both our advisory group and for third parties. As of March 31, 2007, total assets were $340 million and the asset advisory group managed an additional $282 million in total assets.
For more information regarding AmREIT, call Chad Braun at 713-850-1400 or Tripp Sullivan with Corporate Communications Inc. at 615-254-3376.
SOURCE AmREIT
----------------------------------------------
Chad C. Braun of AmREIT
+1-713-850-1400
cbraun@amreit.com
BNVI 4.25 Bionovo, Inc. Joins the Russell 3000 Index
Jun 25, 2007 8:00:00 AM
EMERYVILLE, Calif., June 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, was one of 275 companies added to the Russell 3000 index today.
Membership in the Russell 3000, which remains in place for one year, means that Bionovo will also be automatically added to the Russell 2000(R) and Russell Microcap, as well as the appropriate growth and style indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
Commenting on the news, Isaac Cohen, CEO of Bionovo, made the following statement: "The company is extremely pleased to be considered for this highly coveted inclusion with the Russell Microcap Index as well as the Russell 3000 Index." Cohen also added, "This listing is in line with our goals to become more visible and more proactive towards advocating investor relations activities to maximize shareholder value."
Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.
Founded in 1936, Russell is a subsidiary of Northwestern Mutual Life Insurance Company. Headquartered in Tacoma, Wash., U.S., Russell has principal offices in Amsterdam, Auckland, Hong Kong, Johannesburg, London, Melbourne, New York, Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto.
Russell's indexes are unmanaged and cannot be investing in directly. For more information on Russell indexes, go to http://www.russell.com.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Company Contacts:
Bionovo, Inc.
Jim Stapleton
Chief Financial Officer
Phone: 510.420.4180
jim@bionovo.com
Media:
Katherina Audley
Phone: 415.847.7295
katherina.audley@bionovo.com
SOURCE Bionovo, Inc.
----------------------------------------------
Jim Stapleton
Chief Financial Officer
+1-510-420-4180
jim@bionovo.com
or Media
Katherina Audley
+1-415-847-7295
katherina.audley@bionovo.com
both of Bionovo
Inc.
QTM 3.05 Quantum Introduces DXi7500 Extending Data De-duplication and Replication Benefits Across the Distributed Enterprise
New Disk-Based Backup System Provides Enterprise Scalability, Industry's First Policy-based De-duplication and Integrated Tape Creation
Jun 25, 2007 8:00:00 AM
SAN JOSE, Calif., June 25 /PRNewswire-FirstCall/ -- Quantum Corp. (NYSE: QTM), the leading global specialist in backup, recovery and archive, today announced the DXi7500 enterprise disk backup and replication system, designed to anchor a comprehensive strategy for linking backup, restore and disaster recovery protection across the distributed enterprise. With the addition of the DXi7500, Quantum's DXi-Series becomes the first disk-based backup family to extend the benefits of data de-duplication, remote replication and disk-to-tape creation across a product line that covers distributed sites, midrange environments, and primary data centers.
With a scalable capacity of up to 240 TB, performance of up to 8 TB/hour, a high-availability architecture, and a unique policy-based data de-duplication approach, the DXi7500 provides disk backup capabilities to match the needs of the most demanding enterprise data centers. And because it leverages the same integrated software layer foundation first introduced in Quantum's DXi3500 and DXi5500 disk backup appliances, the DXi7500 can also serve as a secure core repository for centralizing backup and disaster recovery from multiple distributed sites.
By eliminating redundant data, the de-duplication technology in Quantum's DXi-Series portfolio is designed to allow users to retain 10 to 50 times more backup data on fast recovery disk and use existing WANs to replicate backup between sites, reducing or even eliminating the challenge of dealing with removable media at remote sites. With this expansion of Quantum's DXi-Series portfolio, customers can now take advantage of replication and a common management interface to link the DXi3500 and DXi5500 appliances in remote offices and midrange data centers with the highly-scalable DXi7500 systems in enterprise data centers, where media management, disaster recovery, and long-term archive processes can be centralized.
"The value propositions of data de-duplication are abundantly clear, and the technology is fast becoming a requisite for customers investing in disk-based backup solutions," said Arun Taneja, founder and consulting analyst for Taneja Group. "Just when the debate between in-line and post-processing was getting interesting, Quantum introduces the DXi7500, a data de-duplication product that allows the user to choose the method based on policy -- once again letting the customer call the shots. I think the IT industry will love this flexibility."
Policy Based De-duplication and Integrated Tape Creation
Two industry-first features in the DXi7500 are designed to provide more effective centralized management of enterprise data. Other suppliers have chosen to provide either in-line de-duplication, which minimizes disk capacity requirements, or post-processing, which maximizes data ingest rates prior to de-duplication. Quantum's new policy-based de-duplication offers both options, allowing customers to determine the most appropriate de-duplication approach to best suit each application. The DXi7500 offers either in-line or post-process functionality based on the requirements of each backup job, meaning customers no longer must choose between performance and capacity allotment when deciding on a disk-based de-duplication solution. Additionally, as the first in the industry to deliver hardware-based data compression technology for open systems disk-based backup, Quantum continues to evolve this capability in the DXi7500, resulting in even better efficiencies across data reduction and system performance.
Because removable media continues to play a key role in long-term data retention and archiving for enterprise applications, the DXi7500 offers users the option of integrated tape creation, allowing removable media to be written outside the backup window without using the media server or the data center's SAN. In the DXi7500, integrated tape creation maintains full bar-code tracking with the backup application. Quantum is also working closely with Symantec to support its Direct to Tape feature in Veritas NetBackup 6.5. The Direct to Tape feature support will provide the first direct tape creation capability to be both fully automated and under the direct control of a backup software application.
"Quantum's DXi7500 signifies the first time that the benefits of data de-duplication are fully leveraged across the distributed enterprise, and while other vendors have targeted certain segments, they have a difficult time spanning a broader range of needs," said Bill Britts, executive vice president of Sales, Marketing and Service for Quantum. "Quantum has developed its DXi-Series portfolio, with the common foundation of our integrated software layer, to deliver scalability, performance and reliability advantages, as well as industry-first features, to our customers. The common software base also allows us to innovate across platforms and future methods of data protection."
DXi7500 Designed for the Enterprise
Based on a sophisticated architecture offering high availability and redundant hardware, the DXi7500 capacity and performance can be easily customized to address increasing pressure on backup windows and to enable effective replication strategies. The DXi7500 offers the flexibility to meet a broad range of configurations balancing cost, functionality and future growth considerations, with capacity points up to 240 TB in a single system.
Like Quantum's other DXi-Series disk backup and replication solutions, the DXi7500 is designed to be easy to deploy and operate. The system can be presented to the backup software as a NAS mount point (CIFS/NFS), as a VTL with either Fibre Channel or iSCSI connectivity, or across all presentations simultaneously. The DXi-Series is fully compatible with all leading backup applications and does not require that users change their existing backup methodology or infrastructure. The DXi7500 also increases customer flexibility by allowing some features, such as data de-duplication, replication and integrated tape creation, to be licensable options.
As part of a comprehensive solutions set from Quantum, the DXi7500 is supported by a suite of global service offerings. Included as standard are Quantum StorageCare(TM) onsite warranty and StorageCare Guardian, Quantum's proactive remote support solution. Warranty extensions and upgrades, as well as a full portfolio of product integration services, are optional. Quantum plans to ship the DXi7500 in fall 2007.
For more information on Quantum's DXi-Series disk backup and replication portfolio, please visit: http://www.quantum.com/Products/Disk-BasedBackup/DXi-Series/Index.aspx.
About Quantum
Quantum Corp. (NYSE: QTM) is the leading global storage company specializing in backup, recovery and archive. Combining focused expertise, customer-driven innovation, and platform independence, Quantum provides a comprehensive, integrated range of disk, tape, and software solutions supported by a world-class sales and service organization. As a long-standing and trusted partner, the company works closely with a broad network of resellers, OEMs and other suppliers to meet customers' evolving data protection needs. Quantum Corp., 1650 Technology Drive, Suite 700, San Jose, CA 95110, (408) 944-4000, http://www.quantum.com.
Quantum, Quantum DXi-Series appliances, Quantum StorageCare and the Quantum logo are registered trademarks of Quantum Corporation. All other trademarks are the property of their respective owners.
"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, without limitation, statements relating to 1) customer benefits and value to customers from using the Quantum appliance products, 2) customer demand for and Quantum's future sales of such Quantum appliance products, 3) the availability of such Quantum appliance products and 4) Quantum's future leadership position in the industry, are forward-looking statements within the meaning of the Safe Harbor. These statements are based on management's current expectations and are subject to certain risks and uncertainties. As a result, actual results may differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially from those described herein include, but are not limited to, operational difficulties, unforeseen technical limitations, unexpected material deviation in product operation, the ability of competitors to introduce new solutions that compete more successfully with our solutions, and unanticipated changes in customers' needs or requirements. More detailed information about these risk factors, and additional risk factors, are set forth in Quantum's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," on pages 39 to 50 in our Quarterly Report on Form 10-Q filed with the SEC on February 8, 2007 and on pages 14 to 25 in Quantum's Annual Report on Form 10-K filed with the Securities and Exchange Commission on June 12, 2006; and those described in any subsequently filed reports. Such reports contain and identify important factors that could cause actual events and results to differ materially from those contained in our projections or forward-looking statement. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Quantum Corp.
----------------------------------------------
Sean Lamb
Public Relations of Quantum Corp.
+1-408-944-6727
sean.lamb@quantum.com
ATML 5.70 Atmel Extends CAP Family of Customizable Microcontrollers With ARM7-based Product
CAP7 Integrates FPGA Logic, Cuts IC Costs by Over 50%
Jun 25, 2007 8:00:00 AM
COLORADO SPRINGS, Colo., June 25 /PRNewswire-FirstCall/ -- Atmel(R) Corporation (Nasdaq: ATML) announced today that it has extended its CAP family of customizable microcontroller-based System-on-a-Chip products with an ARM7 core. The new CAP7 customizable microcontroller is architecturally compatible with Atmel's broad range of off-the-shelf ARM7-based MCUs and incorporates metal programmable cell fabric (MPCF) technology to integrate up to 450K equivalent ASIC gates in a metal programmable block for custom logic netlist conversion. Atmel's flexible design flow allows an easy conversion path from FPGA netlist to the metal programmable block.
According to Atmel's marketing director, Jay Johnson, "Design engineers frequently use programmable ICs to accelerate their proprietary DSP algorithms in a gate array technology. Many choose FPGAs which represent a flexible, cost-effective solution for market-testing new products, when volumes cannot be predicted. However, once production ramp begins and controlling bill of materials is a priority, our CAP7 customizable MCUs offer a painless cost reduction path, without the typical NRE and long development cycle associated with a standard cell ASIC."
By eliminating an external FPGA, Atmel's customizable microcontrollers can reduce IC costs by at least 50%. For example, in medium volumes (50K units), a 1 to 2M gate FPGA and ARM7 MCU, 2-chip solution, market price is between $13 and $20. With unit prices under $6, CAP7 can cut the cost by more than half. In addition, with an 80MHz CAP7, designers can double performance and reduce power consumption by 90%, compared to 1 to 2 watt FPGA solutions.
Available for ARM7-based Designs. The initial CAP7 product release includes the AT91CAP7S, based on the ARM7TDMI(R) processor core. The AT91CAP7S has 160K bytes of on-chip fast SRAM and either a 250K or 450K block of metal programmable ASIC gates. Peripherals include USB device, SPI master and slave, two USARTs, three 16-bit timer counters, an 8-channel, 10-bit analog to digital converter, and a full complement of supervisory functions. Additional peripherals from Atmel's extensive IP library or customer IP may be instantiated in the MP block.
Availability and Pricing. There is a one-time charge of US $150,000 for design, mask fees, and prototypes. The CAP7 is available now for design. The AT91CAP7S250 in a 144 pin LQFP package is priced at US $5.44 for 50K unit quantities.
About MPCF. The MPCF technology offers the density and unit costs of cell-based ASICs with the quick turn around and low NREs of gate arrays. The key to the MPCF technology is an 8 transistor core cell that is only 3.2 um high and 2.0 um wide in Atmel's 130nm process, achieving densities up to 210,000 usable gates per square millimeter which is 35% more available gates than sea-of-gates technology.
About Atmel
Atmel is a worldwide leader in the design and manufacture of microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets.
(C) 2007 Atmel Corporation. All Rights Reserved. Atmel(R), logo and combinations thereof, and others, are registered trademarks, or trademarks of Atmel Corporation or its subsidiaries. ARM(R), ARM7TDMI(R) and others are registered trademarks or trademarks of ARM Ltd. Other terms and product names may be trademarks of others.
Information:
Atmel's AT91CAP product information may be retrieved at:
http://www.atmel.com/products/AT91CAP/
Press Contacts:
Barbara Bailey, Marketing Communications Manager - USA
Phone: (+1) 719 540 1895, Email: bbailey@cso.atmel.com
Peter Bishop, Communications Manager, Atmel Rousset, France
Phone: (+33) (0) 4 42 53 61 50, Email: peter.bishop@rfo.atmel.com
Veronique Sablereau, Corporate Communications Manager - Europe
Phone: +33 1 30 60 70 68, Email: veronique.sablereau@atmel.com
SOURCE Atmel Corporation
----------------------------------------------
Barbara Bailey
Marketing Communications Manager - USA
+1-719-540-1895
bbailey@cso.atmel.com
or Peter Bishop
Communications Manager
Atmel Rousset
France
(+33) (0) 4 42 53 61 50
peter.bishop@rfo.atmel.com
or Veronique Sablereau
Corporate Communications Manager - Europe
+33 1 30 60 70 68
veronique.sablereau@atmel.com
all of Atmel Corporation
NETM 4.76 NetManage Announces Distribution Agreement With Aquion
Aquion Partnership Expands NetManage Channel Strategy in Australia and New Zealand
Jun 25, 2007 8:00:00 AM
2007 PrimeNewswire, Inc.
CUPERTINO, Calif., June 25, 2007 (PRIME NEWSWIRE) -- NetManage, Inc. (Nasdaq:NETM), a software company that provides the fastest way to transform legacy applications into new Web-based business solutions, today announced that it has signed a distribution agreement with Aquion Pty Ltd, a strategic software provider. With this agreement, Aquion will provide NetManage host access and Web-enabling products in Australia and New Zealand to address the region's growing demand for data integration solutions.
"We deliver business value to our large and established customer base in Australia and New Zealand by providing them access to effective technology applications," said Stephen Balicki, managing director at Aquion. "NetManage provides credible tools to the integration and emulation marketplace that enable the plug-in of legacy applications into modern environments, which continues to drive growth in our region. By distributing NetManage's proven solutions, Aquion is able to better serve our customers in diverse markets with solutions for integrating, Web-enabling and accessing enterprise information systems."
NetManage OnWeb, Librados and RUMBA together offer a complete suite of Web-enabled and integration solutions, leveraging legacy-based mainframe applications to extend the functionality of back-end systems. OnWeb offers a comprehensive development and deployment platform that enables you to create new business services by leveraging your existing enterprise information systems into Web-based applications. NetManage Librados adapters integrate enterprise systems with real time connectivity, improving business processes and lowering operational costs. RUMBA provides all the core functionality of a Windows-based emulator, from multi-session support and host printer emulation to a variety of file transfer and host-based graphics options.
"NetManage provides enterprises with solutions to access valuable legacy data locked in the mainframe along with the ability to leverage that data in dynamic ways, including Web services and host access," said Zvi Alon, president, chairman and CEO of NetManage. "NetManage is committed to expanding our global distribution strategy and successfully impacting the bottom line through strategic partnerships like our newly announced deal with Aquion, a 100 percent channel-focused company."
About Aquion
Aquion Pty Ltd, a technology-focused sales and marketing company, has been supplying award-winning technologies to the Australia, New Zealand and Asian marketplaces since 2000. Aquion markets, sells and supports its vendors' products through a network of Channel Partners which include leading Consultants, Integrators and Services companies. Aquion's customers include Australia and New Zealand's largest organizations. Aquion works with customers to determine an efficient route to market for technologies and ensures that enterprise customers are supported by Services Partners with the appropriate knowledge and skills to ensure business benefit is derived from technologies supplied.
About NetManage
NetManage, Inc. (Nasdaq:NETM), is a software company that provides the fastest way to transform legacy applications into new Web-based business solutions. More than 10,000 customers worldwide, including the majority of the Fortune 500, have chosen NetManage for mission critical application integration. For more information, visit www.netmanage.com.
NetManage, the NetManage logo, the lizard-in-the-box logo, Chameleon and Chameleon design, RUMBA, ONESTEP, ViewNow, SupportNow, Librados, and OnWeb are either trademarks or registered trademarks of NetManage, Inc. in the United States and/or other countries. All other trademarks are the property of their respective owners.
The NetManage logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2691
This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties, including statements regarding improvement in the Company's competitive position, improvement in financial results and business pipeline, the Company's positioning in its market, and the progress and benefits of the Company's execution on its business plan. The Company's actual results could differ materially from the results discussed in the forward-looking statements. The factors that could cause or contribute to such differences include, among others, that competitive pressures continue to increase, that the markets for the Company's products could grow more slowly than the Company or market analysts believe, that the Company is unable to integrate or take advantage of its acquisitions successfully, or that the Company will not be able to take advantage of growth in the Company's target markets. Additional information on these and other risk factors that could affect the Company's financial results is included in the Company's Annual Report on Form 10-K, Forms 10-Q, Forms 8-K and other documents filed with the Securities and Exchange Commission.
CONTACT: Schwartz Communications
NetManage Media Inquiries:
Mary-Katharine Juric
(415) 512-0770
netmanage@schwartz-pr.com
DUSA 3.01 DUSA Pharmaceuticals to Present at the Jefferies Healthcare Conference on June 28
Jun 25, 2007 8:00:00 AM
WILMINGTON, MASSACHUSETTS -- (MARKETWIRE) -- 06/25/07 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announced today that Robert F. Doman, President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Thursday, June 28, 2007 at 11:20 a.m. Eastern Daylight Time in New York, NY.
Live Audio Webcast
The presentation will be available as a live audio webcast on the Company's website at www.dusapharma.com and a copy of the slide presentation together with the audio will be archived on the Company's website following the presentation.
About DUSA
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2) of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach(TM), Nicomide® and the AVAR® line. DUSA is also sponsoring research for additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.
Contacts:
DUSA Pharmaceuticals, Inc.
Shari Lovell
Director, Shareholder Services
(416) 363-5059
(416) 363-6602 (FAX)
Email: lovells@dusapharma.com
Website: www.dusapharma.com
MNG 4.39 Miramar Reports Licensing for Doris North Gold Mine Progresses
Pre-Development Construction Continues
Jun 25, 2007 8:00:00 AM
VANCOUVER, BRITISH COLUMBIA -- (MARKETWIRE) -- 06/25/07 -- Miramar Mining Corporation (TSX: MAE)(AMEX: MNG) today announced the progress of an important step in the licensing procedure for Doris North. After technical meetings held last week in Cambridge Bay, Nunavut, The Nunavut Water Board ("NWB") has confirmed that the Doris North Water License application will proceed to public hearings in Cambridge Bay on August 13 - 15, 2007.
The Doris North Mine received environmental approval from the Nunavut Impact Review Board and the Minister of Indian and Northern Affairs Canada in September 2006 after rigorous environmental assessment on all aspects of the project. Miramar is now in the regulatory phase of licensing and permitting for the project and has been working on the various applications for the same.
Obtaining a water license from the NWB is essential to construction and operations at Doris North. Miramar submitted its water license application to the NWB late in 2006 and after providing further requested information in a re-submission earlier this year, the NWB, Miramar and various regulatory agencies involved in the process, attended for a pre-hearing conference in Cambridge Bay last week.
This technically focused conference involved representatives of Indian and Northern Affairs Canada, the Federal Department of Fisheries and Oceans, Environment Canada, the Government of Nunavut/Department of the Environment, Nunavut Tunngavik Inc. and the Kitikmeot Inuit Association. During the conference, Miramar provided an update as well as proposed modifications to the project to the parties. In turn, Miramar was asked to provide further information relating to these modifications.
In the result, all parties confirmed that subject to receipt of said information requests, there are no major technical issues or material information requirements and that the application for the Doris North Water License should proceed to public hearings. In its decision announced last Friday, the NWB have confirmed the hearings will take place in Cambridge Bay, Nunavut on August 13 - 15, 2007.
As permitting continues to move forward for the Doris North Mine, Miramar has proceeded with the purchase of long lead time items for the project and is beginning site preparation at Hope Bay. Predevelopment work consists of preparing the lay down area at Roberts Bay, constructing the road to the marine jetty and opening of a Quarry to provide the rock material for this construction. The objective is to create an area where the construction equipment and material can be offloaded and stored in preparation for full construction once the Water License has been issued. The marine jetty is scheduled to be constructed in July once the regulatory authorizations arrive.
It is anticipated that the first mobilization of building equipment and supplies will arrive by sea-lift in August 2007. Material shipped on the barge includes the accommodation camp (modular trailer units), the mill building, earth moving equipment, construction cranes, concrete, steel, fuel and other materials to support construction.
"Although we have not received all of our final licenses for Doris North, we are very encouraged by the commitment of all the agencies involved to maintaining regulatory responsibility while balancing the need to move the process for Doris North forward," said Tony Walsh, Miramar's President and CEO. "The Doris North Mine is the first contemplated mine on the Hope Bay belt and is what we hope will be the first new gold mine in the territory of Nunavut. We are excited that we are finally moving ground for Doris North and look forward to the many opportunities Hope Bay has to offer Miramar and Nunavut."
Miramar Mining Corporation
Miramar is a Canadian gold company that controls the Hope Bay project, the largest undeveloped gold project in Canada. The Hope Bay project extends over 1,000 sq. km. and encompasses one of the most prospective undeveloped greenstone belts in Canada.
Forward Looking Statements
Statements relating to licensing and permitting process for the Doris North Mine and the expected program for 2007 are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and securities legislation in certain provinces in Canada. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Information inferred from the interpretation of drilling results and information concerning mineral resource estimates may also be deemed to be forward looking statements, as it constitutes a prediction of what might be found to be present when and if a project is actually developed. These forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation: risks related to fluctuations in gold prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work resulting from weather, logistical, technical or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the Company's properties; uncertainties involved in the interpretation of drilling results and other tests and the estimation of gold reserves and resources; the need for continued cooperation of regulatory authorities and the possibility that required permits may not be obtained on a timely manner or at all; the possibility that capital and operating costs may be higher than currently estimated and may preclude commercial development or render operations uneconomic; the possibility that the estimated recovery rates may not be achieved; risk of accidents, equipment breakdowns and labour disputes or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in the work program; the risk of environmental contamination or damage resulting from Miramar's operations and other risks and uncertainties, including those described in the Miramar's Annual Report on Form 40-F for the year ended December 31, 2006 and Reports on Form 6-K filed with the Securities and Exchange Commission.
Forward-looking statements are based on the beliefs, estimates and opinions of Miramar's management on the date the statements are made. Miramar undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
This news release has been authorized by the undersigned on behalf of Miramar Mining Corporation.
Contacts:
Miramar Mining Corporation
Anthony P. Walsh
President & CEO
(604) 985-2572 or Toll Free: 1-800-663-8780
(604) 980-0731 (FAX)
Email: info@miramarmining.com
Website: www.miramarmining.com
PRCP 9.79 Perceptron Appoints Vice President and Chief Financial Officer
Jun 25, 2007 8:00:00 AM
PLYMOUTH, MI -- (MARKETWIRE) -- 06/25/07 -- Perceptron, Inc. (NASDAQ: PRCP) today announced the appointment of John H. Lowry III as Vice President and Chief Financial Officer. Mr. Lowry joins the Company from Catuity, Inc., a provider of I.T. software and services, where he served as Vice President and Chief Financial Officer since 2000.
Prior to Catuity, from August 1992 to January 2000, Mr. Lowry was Vice President - Finance for Kelly Services Inc., a staffing services company, where he was responsible for the financial activities for operations of over 500 staffing offices in 190 cities with annual sales exceeding $800 million. From August 1982 to August 1992 he was Corporate Controller for Crain Communications Inc., a magazine publishing company in Michigan. Prior to this he was a Senior Manager at Arthur Andersen & Co. Mr. Lowry holds a Master's degree in Business Administration and a Bachelor's degree in Engineering from the University of Michigan.
"We are excited to have someone of Jack's caliber join our Company," said Alfred A. Pease, chairman, president and chief executive officer. "He brings with him a wealth of financial and operational experience, gained in public corporations as large as $5.0 billion. He is expected to play a key role in Perceptron's continued growth."
About Perceptron
Perceptron develops, produces and sells non-contact measurement and inspection solutions for industrial and commercial applications. The Company's Automated Systems Products provide solutions for manufacturing process control as well as sensor and software technologies for non-contact measurement and inspection applications. Automotive and manufacturing companies throughout the world rely on Perceptron's metrology solutions to help them manage their complex manufacturing processes to improve quality, shorten product launch times and reduce overall manufacturing costs. Perceptron's Technology Products provide innovative solutions for scanning and inspection, serving industrial, trade and customer support services. The Company also offers Value Added Services such as training and customer support services. Headquartered in Plymouth, Michigan, Perceptron has approximately 245 employees worldwide, with operations in the United States, Germany, France, Spain, Brazil, Japan, Singapore and China. For more information, please visit www.perceptron.com.
CONTACT:
Alfred A. Pease
Chairman, President & CEO
734 414-6100
CTCH 1.83 Commtouch CEO to Present at C.E. Unterberg, Towbin Emerging Growth Conference, New York
Jun 25, 2007 8:00:00 AM
Copyright Business Wire 2007
SUNNYVALE, Calif.--(BUSINESS WIRE)--
Commtouch(R) (NASDAQ:CTCH) CEO and Chairman of the Board Gideon Mantel has been invited to present at the 2007 C.E. Unterberg, Towbin Emerging Growth Conference, taking place July 10-12, at the Mandarin Oriental Hotel in New York City.
Mr. Mantel will present on Tuesday, July 10, at 8:30 AM.
The prestigious invitation-only event is designed to facilitate maximum meeting opportunities between investors and managements of 145 select emerging growth companies.
The presentation will be broadcast live on the Internet by Wall Street Webcasting, and may be accessed at http://www.wsw.com/webcast/ceut6/ctch/.
C.E. Unterberg, Towbin is a full-service investment bank serving emerging growth companies in the technology, health care and defense, security and diversified technology sectors. For more information about the Emerging Growth Conference, see http://www.unterberg.com/newsperspec/news_upcoming.asp.
About Commtouch
Commtouch Software Ltd. (Nasdaq:CTCH) is dedicated to protecting and preserving the integrity of the world's most important communications tool -- email. Commtouch has over 16 years of experience developing messaging software and is a global developer and provider of proprietary anti-spam, Zero-Hour virus protection and Reputation Service solutions. Using core technologies including RPD(TM) (Recurrent Pattern Detection), the Commtouch Detection Center analyzes billions of email messages per month to identify new spam and malware outbreaks within minutes of their introduction into the Internet. Integrated by scores of OEM partners, Commtouch technology protects thousands of organizations, with over 50 million users in over 100 countries. Commtouch is headquartered in Netanya, Israel, and has a subsidiary in Sunnyvale, CA. For more information, see: www.commtouch.com, including the Commtouch online lab detailing spam statistics and charts.
Source: Commtouch Software Ltd.
----------------------------------------------
Commtouch Software Ltd.
Rebecca Steinberg Herson
650-864-2112 (US)
or +972-9-863-6877 (Int'l)
rebeccah@commtouch.com
RZ 7.68 Raser Secures Five New Geothermal Leases in Utah
Jun 25, 2007 8:00:00 AM
Copyright Business Wire 2007
PROVO, Utah--(BUSINESS WIRE)--
Raser Technologies, Inc. (NYSE Arca: RZ) announced today that it has secured additional geothermal rights in Utah under the terms of five lease agreements.
Raser has secured the rights to the geothermal resources on 9,370 acres located in two counties in Southern Utah. The lease terms are up to ten years and are renewable for additional periods based on development activity or upon the payment of minimum rental payments. The financial terms of the leases are undisclosed. These leases bring the total land Raser has under lease in Utah alone for geothermal development to over 37,000 acres.
"We have established what we believe to be one of the most attractive undeveloped geothermal resource portfolios in the U.S.," stated Brent M. Cook, Raser's CEO, "and we plan to continue expanding our portfolio as we identify new, attractive properties to ensure that we have the geothermal resources sufficient to meet our goals in the development of renewable power plants."
About Raser Technologies
Raser (NYSE Arca: RZ) is a publicly-traded, green-focused technology licensing and development company operating in two business segments. Raser's Transportation and Industrial Technology segment focuses on using Raser's Symetron(TM) technology to improve the efficiency of electric motors and other applications. Raser's Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser's Symetron(TM) technology. Further information on Raser may be found at: www.rasertech.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the potential for geothermal power generation on our leased properties; our belief about our ability to exploit the available geothermal resources; our beliefs about the strength and enforceability of our agreements; and our beliefs about the geothermal market generally. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology for geothermal applications; our ability to secure necessary permits; the strength of our intellectual property; our inability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended March 31, 2007, as filed with the Securities and Exchange Commission, and all subsequent filings.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Source: Raser Technologies, Inc.
----------------------------------------------
Raser Technologies
Inc.
Investor Relations
801-765-1200
investorrelations@rasertech.com
or
Porter
LeVay & Rose
Inc.
Andrew Berlin
Account Executive
Jeffrey Myhre
VP - Editorial
212-564-4700
or
Tom Gibson
VP - Media Relations
201-476-0322
Fax: 212-244-3075
www.plrinvest.com
plrmail@plrinvest.com
VVUS 4.98 VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
A Retrospective Review of Data from Obese Diabetic Patients Treated in Private Clinic Practice with Topiramate plus Phentermine
Jun 25, 2007 7:45:00 AM
Copyright Business Wire 2007
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Abstract #2209-PO, Evaluation of Glycemic Parameters in Obese Diabetic Patients Treated with Phentermine and Topiramate: Outcomes in a Private Practice Setting has been published in the American Diabetes Association 2007 Scientific Sessions Abstract book. The abstract is available on the American Diabetes Association website.
The purpose of analyzing these data compiled from Dr. Najarian's private medical practice was to evaluate the glycemic effects of topiramate plus phentermine in type 2 diabetic patients with metabolic co-morbidities. The abstract was based on a series of consecutive obese type 2 diabetic patients that had both baseline and on-treatment HbA1c measurements. The results showed that topiramate plus phentermine reduced HbA1c levels and the need for other anti-diabetic medications. Metabolic co-morbidities were also reduced.
About Dr. Najarian
Thomas Najarian, M.D., a Board Certified Specialist in Internal Medicine, is a graduate of MIT (SB, SM in Mechanical Engineering) and Harvard Medical School. He is a former faculty member of the Harvard Medical School. Dr. Najarian was the former Medical Director and Vice-President of Medical Affairs at Interneuron Pharmaceuticals (now Indevus Pharmaceuticals). He is the author of many scientific publications as well as the holder of several U.S. and international patents. Dr. Najarian has 25 years experience in treating obesity and discovered the proprietary combination of topiramate plus phentermine for the treatment of obesity and related conditions. In 2001, VIVUS in-licensed Dr. Najarian's invention and intellectual property associated therewith in exchange for certain milestone payments, stock options and future royalty payments based on product sales. In May of 2006, Dr. Najarian was hired by VIVUS as part-time Principal Scientist. VIVUS is currently developing Qnexa, which is a proprietary pharmaceutical treatment that is a combination of low doses of phentermine and topiramate that is being investigated for the treatment of obesity. The abstract discussed by Dr. Najarian and published in the American Diabetes Association 2007 Scientific Sessions abstract book was not based on Qnexa. VIVUS provided funding for Dr. Najarian's analysis.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms, and on May 15, 2007, the EvaMist assets were transferred to KV Pharmaceutical Company; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE(R) is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the EvaMist NDA submission will be approved in a timely basis, or at all. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10- K for the year ended December 31, 2006 and periodic reports filed with the Securities and Exchange Commission.
Source: VIVUS, Inc.
----------------------------------------------
VIVUS
Inc.
Timothy E. Morris
650-934-5200
Chief Financial Officer
or
The Trout Group
Ian Clements (SF)
415-392-3385
Brian Korb (NYC)
646-378-2923
TSYS 5.28 TCS Appoints Barry Dowdy as Vice President of SwiftLink(R) Deployable Communication Systems Division
Jun 25, 2007 7:30:00 AM
ANNAPOLIS, MD -- (MARKETWIRE) -- 06/25/07 -- TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a leading provider of mission-critical wireless data solutions, today announced the company has hired Barry Dowdy as Vice President of SwiftLink� Deployable Communications Systems, a division of TCS' Government Solutions Group. In this position, Dowdy is responsible for TCS' deployable communications business unit, including management of engineering, production and SATCOM services and is responsible for the unit's Project Management Office, Partner Relations and the Product and Services Board.
Prior to joining TCS, Dowdy served as a Communications Officer in the United States Marine Corps. Dowdy retired in 2007 with the rank of Major. His last assignment was at Marine Corps Systems Command as a Program Manager with responsibility for such programs as Common Army Marine Command & Control (CAMC2) and Command and Control On-the-move Network Digital Over-the-horizon Relay (CONDOR). He earned his Level II Defense Acquisition Professional Certification in 2005 and Program Management Professional Certification in 2007.
"TCS is focused on maintaining a strong leadership team to support the substantial growth we've seen over the past year," said Michael Bristol, Senior Vice President, TCS Government Solutions Group. "Barry Dowdy brings a proven military track record and is well respected within the government industry sector. As TCS is witnessing rapid growth in our Government Solutions Group, Barry is a strong and capable addition to the team."
Dowdy graduated from The Citadel and holds a Bachelor of Science in Electrical Engineering. He was commissioned a Second Lieutenant in May 1995. Dowdy also graduated from the Naval Postgraduate School (NPS) in Monterey, Calif., in June 2003.
"TCS has built a strong relationship with the government, providing some of the best deployable systems available on the market today," said Barry Dowdy, Vice President of SwiftLink Deployable Communication Systems for TCS Government Solutions Group. "I look forward to leveraging my expertise and experience to provide the public-sector with superior telecommunication solutions."
ABOUT TELECOMMUNICATION SYSTEMS, INC.
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) produces wireless data communications technology solutions that require proven high levels of reliability. TCS provides wireless and VoIP E9-1-1 network-based services, secure deployable communication systems and engineered satellite-based services, and commercial location applications, like traffic and navigation, using the precise location of a wireless device. Customers include leading wireless and VoIP operators around the world, and agencies of the U.S. Departments of Defense, State, and Homeland Security.
Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon the companies' current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include the statement that TCS is experiencing rapid growth in its Government Solutions Group, and those detailed from time to time in the Company's SEC reports such as form 10-K for the period ending December 31, 2006 and form 10-Q for the quarter ending March 31, 2007.
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The companies undertake no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.
Media Contacts:
Rita Thompson
TeleCommunication Systems, Inc.
410-295-1865
rthompson@telecomsys.com
Jane Bryant/Evan Weisel
Welz & Weisel Communications
703-218-3555
jane@w2comm.com
$222.20 in Prize money for picking the time of post #222,222,222... Go to IHUB Milestone Board and cast your prediction NOW!!! Pass it On!! http://www.investorshub.com/boards/board.asp?board_id=1594
$222.20 in Prize money for picking the time of post #222,222,222... Go to IHUB Milestone Board and cast your prediction NOW!!! Pass it On!! http://www.investorshub.com/boards/board.asp?board_id=1594
well wishes to 500_and_long!!
Sent By: 500_and_Long Date: 6/23/2007 10:57:25 AM
Got sick on my trip (some sort of virus??) in the hospital but hope to be back soon. Tell everyone I'l log on when I can.